p NN O
venkatarama NN O
reddi NN O
j NN O
11 CD O
these DT O
appeals NNS O
by IN O
special JJ O
leave NNS O
preferred VBN O
by IN O
the DT O
union NN O
of IN O
india NNS O
are VBP O
directed VBN O
against IN O
the DT O
common JJ O
judgment NN O
of IN O
the DT O
bombay JJ O
high JJ O
court NN O
in IN O
a DT O
batch NN O
of IN O
writ JJ O
petitions NNS O
filed VBN O
under IN O
article NN O
226 CD O
of IN O
the DT O
constitution NN O
by IN O
the DT O
manufacturers NNS O
importers NNS O
of IN O
certain JJ O
bulk NN O
drugs NNS O
and CC O
their PRP$ O
formulations NNS O
the DT O
bulk NN O
drugs NNS O
concerned VBN O
are VBP O
seven CD O
in IN O
number NN O
they PRP O
are VBP O
salbutamol JJ O
theophylline JJ O
cyproflaxacin NN O
norfloxacin JJ O
cloxacillin NN O
doxycycline NN O
and CC O
glipizide VB O
these DT O
bulk NN O
drugs NNS O
and CC O
the DT O
formulations NNS O
made VBD O
out IN O
of IN O
them PRP O
are VBP O
sold VBN O
within IN O
the DT O
country NN O
and CC O
part NN O
of IN O
the DT O
quantities NNS O
produced VBN O
are VBP O
also RB O
exported VBN O
outside IN O
the DT O
country NN O
the DT O
challenge NN O
is VBZ O
to TO O
the DT O
inclusion NN O
of IN O
the DT O
said VBD O
bulk NN O
drugs NNS O
in IN O
the DT O
first JJ O
schedule NN O
to TO O
the DT O
drugs NNS O
price NN O
control NN O
order NN O
1995 CD O
hereinafter NN O
referred VBD O
to TO O
as IN O
the DT O
dpco NN O
though IN O
the DT O
fixation NN O
of IN O
priced VBN O
pursuant NN O
to TO O
the DT O
provisions NNS O
of IN O
the DT O
said VBD O
order NN O
was VBD O
also RB O
challenged VBN O
in IN O
some DT O
of IN O
the DT O
writ NN O
petitions NNS O
that IN O
issue NN O
was VBD O
not RB O
gone VBN O
into IN O
by IN O
the DT O
high JJ O
court NN O
and CC O
at IN O
any DT O
rate NN O
the DT O
mechanics NNS O
of IN O
price NN O
fixation NN O
is VBZ O
not RB O
the DT O
contentious JJ O
issue NN O
before IN O
us PRP O
however RB O
it PRP O
may MD O
be VB O
noted VBN O
that IN O
the DT O
remedy NN O
by IN O
way NN O
of IN O
review NN O
is VBZ O
available JJ O
under IN O
paragraph NN O
22 CD O
of IN O
the DT O
dpco NN O
to TO O
seek VB O
reconsideration NN O
of IN O
price NN O
fixation NN O
the DT O
immediate JJ O
provocation NN O
for IN O
filing VBG O
the DT O
writ NN O
petitions NNS O
in IN O
the DT O
high JJ O
court NN O
seems VBZ O
to TO O
be VB O
the DT O
notices NNS O
issued VBN O
by IN O
the DT O
national JJ O
pharmaceutical JJ O
pricing NN O
authority NN O
calling VBG O
upon IN O
some DT O
of IN O
the DT O
national JJ O
pharmaceutical JJ O
pricing NN O
authority NN O
calling VBG O
upon IN O
some DT O
of IN O
the DT O
respondent NN O
companies NNS O
to TO O
deposit VB O
the DT O
overcharged JJ O
amounts NNS O
in IN O
relation NN O
to TO O
the DT O
formulations NNS O
of IN O
scheduled JJ O
drugs NNS O
12 CD O
the DT O
high JJ O
court NN O
held VBD O
that IN O
the DT O
concerned JJ O
drugs NNS O
should MD O
not RB O
have VB O
been VBN O
brought VBN O
within IN O
the DT O
purview NN O
of IN O
the DT O
dpco NN O
1995 CD O
and CC O
consequently RB O
there EX O
could MD O
be VB O
no DT O
fixation NN O
of IN O
price NN O
in IN O
relation NN O
to TO O
those DT O
drugs NNS O
the DT O
notices NNS O
demanding VBG O
overcharged JJ O
amounts NNS O
were VBD O
quashed VBN O
the DT O
writ NN O
petitions NNS O
were VBD O
thus RB O
allowed VBN O
by IN O
the DT O
division NN O
bench NN O
of IN O
high JJ O
court NN O
21 CD O
the DT O
dpco NN O
1995 CD O
which WDT O
came VBD O
into IN O
force NN O
on IN O
6th CD O
january JJ O
1995 CD O
was VBD O
promulgated VBN O
by IN O
the DT O
central JJ O
government NN O
in IN O
exercise NN O
of IN O
the DT O
powers NNS O
conferred VBN O
by IN O
section NN O
3 CD O
of IN O
the DT O
essential JJ O
commodities NNS O
act VBP O
it PRP O
repealed VBD O
the DT O
earlier JJR O
dpco NN O
of IN O
1987 CD O
under IN O
which WDT O
more RBR O
number NN O
of IN O
drugs NNS O
were VBD O
subjected VBN O
to TO O
price NN O
control NN O
drug NN O
as IN O
defined VBN O
in IN O
drugs NNS O
cosmetics NNS O
act NN O
is VBZ O
one CD O
of IN O
the DT O
essential JJ O
commodities NNS O
22 CD O
according VBG O
to TO O
section NN O
2a CD O
of IN O
dpco JJ O
bulk JJ O
drug NN O
means VBZ O
any DT O
pharmaceutical JJ O
chemical NN O
biological NN O
or CC O
plant NN O
product NN O
including VBG O
its PRP$ O
salts NNS O
esters NNS O
stereo VBP O
isomers NNS O
and CC O
derivatives NNS O
conforming VBG O
to TO O
pharmacopoeia VB O
or CC O
other JJ O
standards NNS O
specified VBN O
in IN O
the DT O
second JJ O
schedule NN O
to TO O
the DT O
drugs NNS O
and CC O
cosmetics NNS O
act NN O
1940 CD O
and CC O
which WDT O
is VBZ O
used VBN O
as IN O
such JJ O
or CC O
as IN O
an DT O
ingredient NN O
in IN O
any DT O
formulation NN O
formulation NN O
is VBZ O
defined VBN O
to TO O
mean VB O
a DT O
medicine NN O
processed VBN O
out IN O
of IN O
or CC O
containing VBG O
one CD O
of IN O
more JJR O
bulk JJ O
drug NN O
or CC O
drugs NNS O
with IN O
or CC O
without IN O
the DT O
use NN O
of IN O
any DT O
pharmaceutical JJ O
aids NNS O
for IN O
internal JJ O
or CC O
external JJ O
use NN O
in IN O
the DT O
diagnosis NN O
treatment NN O
mitigation NN O
or CC O
prevention NN O
of IN O
disease NN O
in IN O
human JJ O
beings NNS O
or CC O
animals NNS O
23 CD O
paragraph JJ O
3 CD O
of IN O
dpco NN O
empowers NNS O
the DT O
central JJ O
government NN O
to TO O
fix VB O
from IN O
time NN O
to TO O
time NN O
a DT O
maximum JJ O
sale NN O
price NN O
at IN O
which WDT O
the DT O
bulk NN O
drug NN O
specified VBN O
in IN O
the DT O
first JJ O
schedule NN O
shall MD O
be VB O
sold VBN O
after IN O
making VBG O
such JJ O
inquiry NN O
as IN O
it PRP O
deems VBZ O
fit JJ O
the DT O
opening NN O
clause NN O
of IN O
sub NN O
para NN O
1 CD O
spells NNS O
out IN O
the DT O
avowed JJ O
purpose NN O
of IN O
price NN O
control NN O
on IN O
the DT O
scheduled JJ O
bulk NN O
drugs NNS O
the DT O
declared JJ O
objective NN O
is VBZ O
to TO O
regulate VB O
the DT O
equitable JJ O
distribution NN O
and CC O
increasing VBG O
supplies NNS O
of IN O
the DT O
specified JJ O
bulk JJ O
drug NN O
and CC O
making VBG O
them PRP O
available JJ O
at IN O
a DT O
fair JJ O
price NN O
there EX O
is VBZ O
a DT O
prohibition NN O
against IN O
the DT O
sale NN O
of IN O
bulk JJ O
drug NN O
at IN O
a DT O
price NN O
exceeding VBG O
the DT O
maximum JJ O
sale NN O
price NN O
fixed VBN O
under IN O
sub NN O
paragraph NN O
1 CD O
plus CC O
local JJ O
taxes NNS O
if IN O
any DT O
as IN O
already RB O
observed VBN O
we PRP O
are VBP O
not RB O
concerned VBN O
here RB O
with IN O
the DT O
modalities NNS O
of IN O
fixation NN O
of IN O
price NN O
the DT O
very JJ O
inclusion NN O
of IN O
these DT O
bulk NN O
drugs NNS O
in IN O
the DT O
schedule NN O
is VBZ O
being VBG O
assailed VBN O
on IN O
the DT O
ground NN O
that IN O
it PRP O
is VBZ O
opposed VBN O
to TO O
the DT O
norms NNS O
laid VBD O
down RB O
by IN O
the DT O
central JJ O
government NN O
itself PRP O
in IN O
the DT O
drug NN O
policy NN O
of IN O
1994 CD O
and CC O
therefore VB O
the DT O
delegated JJ O
legislative JJ O
power NN O
exercised VBN O
by IN O
the DT O
government NN O
is VBZ O
arbitrary JJ O
and CC O
violative NN O
of IN O
article NN O
14 CD O
of IN O
the DT O
constitution NN O
the DT O
plea NN O
of IN O
the DT O
respondents NNS O
was VBD O
accepted VBN O
by IN O
the DT O
high JJ O
court NN O
24 CD O
in IN O
the DT O
drug NN O
policy NN O
document NN O
issued VBN O
on IN O
15th CD O
september NN O
1994 CD O
the DT O
central JJ O
government NN O
noticed VBD O
that IN O
during IN O
the DT O
last JJ O
decade NN O
the DT O
drug NN O
industry NN O
had VBD O
grown VBN O
significantly RB O
in IN O
terms NNS O
of IN O
production NN O
of IN O
bulk NN O
drugs NNS O
and CC O
formulations NNS O
and CC O
the DT O
export NN O
performance NN O
of IN O
the DT O
industry NN O
had VBD O
been VBN O
commendable JJ O
it PRP O
was VBD O
said VBD O
that IN O
the DT O
pharmaceutical JJ O
sector NN O
had VBD O
been VBN O
able JJ O
to TO O
carve VB O
a DT O
special JJ O
niche NN O
for IN O
itself PRP O
in IN O
the DT O
international JJ O
market NN O
as IN O
a DT O
dependable JJ O
exporter NN O
of IN O
bulk NN O
drugs NNS O
the DT O
drug NN O
policy NN O
with IN O
regard NN O
to TO O
pricing NN O
has VBZ O
been VBN O
stated VBN O
thus RB O
in IN O
paragraph JJ O
9 CD O
of IN O
the DT O
policy NN O
paper NN O
9 CD O
pricing VBG O
the DT O
aberrations NNS O
which WDT O
have VBP O
come VBN O
to TO O
notice VB O
in IN O
the DT O
listing NN O
of IN O
drugs NNS O
and CC O
their PRP$ O
categorization NN O
for IN O
the DT O
purpose NN O
of IN O
price NN O
control NN O
need NN O
to TO O
be VB O
eliminated VBN O
by IN O
the DT O
use NN O
of IN O
transparent JJ O
criteria NNS O
applied VBN O
across IN O
the DT O
board NN O
on IN O
all PDT O
the DT O
drugs NNS O
with IN O
the DT O
minimum JJ O
use NN O
of IN O
subjectively RB O
the DT O
high JJ O
turnover NN O
of IN O
a DT O
drug NN O
is VBZ O
in IN O
index NN O
of IN O
its PRP$ O
extent NN O
of IN O
usage NN O
and CC O
is VBZ O
considered VBN O
to TO O
meet VB O
the DT O
requirements NNS O
of IN O
objectivity NN O
justifiable NN O
on IN O
economic JJ O
considerations NNS O
however RB O
the DT O
monopoly NN O
situation NN O
in IN O
cases NNS O
of IN O
drugs NNS O
with IN O
comparatively RB O
lower JJR O
turnover NN O
has VBZ O
also RB O
to TO O
be VB O
kept VBN O
in IN O
view NN O
also RB O
as IN O
an DT O
experimental JJ O
measure NN O
drugs NNS O
having VBG O
adequate JJ O
competition NN O
may MD O
not RB O
be VB O
kept VBN O
under IN O
price NN O
control NN O
and CC O
if IN O
this DT O
proves VBZ O
successful JJ O
it PRP O
would MD O
pave VB O
the DT O
way NN O
for IN O
further JJ O
liberalization NN O
in IN O
the DT O
event NN O
however RB O
of IN O
prices NNS O
of IN O
these DT O
drugs NNS O
not RB O
remaining VBG O
within IN O
reasonable JJ O
limits NNS O
the DT O
government NN O
would MD O
reclaim VB O
price NN O
control NN O
in IN O
paragraph NN O
11 CD O
it PRP O
is VBZ O
stated VBN O
in IN O
the DT O
light NN O
of IN O
the DT O
apprehensions NNS O
expressed VBN O
in IN O
the DT O
parliament NN O
on IN O
the DT O
likely JJ O
spurt NN O
in IN O
the DT O
pieces NNS O
of IN O
medicines NNS O
it PRP O
has VBZ O
benefit NN O
that IN O
it PRP O
would MD O
not RB O
be VB O
desirable JJ O
to TO O
allow VB O
automatically RB O
in IN O
the DT O
pricing NN O
mechanism NN O
the DT O
government NN O
would MD O
set VB O
up RP O
an DT O
independent JJ O
body NN O
of IN O
experts NNS O
to TO O
be VB O
called VBN O
the DT O
national JJ O
pharmaceutical JJ O
pricing NN O
authority NN O
to TO O
do VB O
the DT O
work NN O
of IN O
price NN O
fixation NN O
this DT O
expert NN O
body NN O
would MD O
also RB O
be VB O
entrusted VBN O
with IN O
the DT O
task NN O
of IN O
updating VBG O
the DT O
list NN O
of IN O
drugs NNS O
under IN O
price NN O
control NN O
each DT O
year NN O
on IN O
the DT O
basis NN O
of IN O
the DT O
established VBN O
criteria NNS O
guidelines NNS O
25 CD O
the DT O
government NN O
s VBD O
resolve NN O
to TO O
closely RB O
monitor VB O
the DT O
trends NNS O
of IN O
prices NNS O
of IN O
medicines NNS O
and CC O
to TO O
take VB O
appropriate JJ O
measures NNS O
to TO O
reclaim VB O
price NN O
control NN O
in IN O
case NN O
the DT O
prices NNS O
of IN O
such JJ O
medicines NNS O
rise NN O
unreasonably RB O
has VBZ O
been VBN O
stressed VBN O
in IN O
paragraph NN O
12 CD O
then RB O
we PRP O
come VBP O
to TO O
the DT O
most RBS O
important JJ O
paragraph NN O
in IN O
the DT O
drug NN O
policy NN O
ie NN O
2272 CD O
which WDT O
bears VBZ O
the DT O
heading VBG O
span NN O
of IN O
control NN O
it PRP O
sets VBZ O
out RP O
the DT O
criteria NNS O
for IN O
bringing VBG O
the DT O
drugs NNS O
under IN O
price NN O
control NN O
we PRP O
quote VBP O
paragraph IN O
2272 CD O
2272 CD O
span NN O
of IN O
control NN O
i VBP O
the DT O
criteria NNS O
of IN O
including VBG O
drugs NNS O
under IN O
price NN O
control NN O
would MD O
be VB O
the DT O
minimum JJ O
annual JJ O
turnover NN O
of IN O
rs JJ O
400 CD O
lakhs JJ O
ii NN O
drugs NNS O
of IN O
popular JJ O
use NN O
in IN O
which WDT O
there EX O
is VBZ O
a DT O
monopoly JJ O
situation NN O
be VB O
kept VBN O
under IN O
price NN O
control NN O
for IN O
this DT O
purpose NN O
for IN O
any DT O
bulk JJ O
drug NN O
having VBG O
an DT O
annual JJ O
turnover NN O
of IN O
rs JJ O
100 CD O
lakhs NN O
or CC O
more JJR O
there EX O
is VBZ O
a DT O
single JJ O
formulator NN O
having VBG O
90 CD O
or CC O
more JJR O
market NN O
share NN O
in IN O
the DT O
retail JJ O
trade NN O
as IN O
per IN O
org IN O
a DT O
monopoly JJ O
situation NN O
would MD O
be VB O
considered VBN O
as IN O
existing VBG O
iii NN O
drugs NNS O
in IN O
which WDT O
there EX O
is VBZ O
sufficient JJ O
market NN O
competition NN O
viz NN O
at IN O
least JJS O
5 CD O
bulk JJ O
drug NN O
producers NNS O
and CC O
at IN O
least JJS O
10 CD O
formulators NNS O
and CC O
none NN O
having VBG O
more JJR O
than IN O
the DT O
40 CD O
market NN O
share NN O
in IN O
the DT O
retail JJ O
trade NN O
as IN O
per IN O
org NN O
may MD O
be VB O
kept VBN O
outside IN O
the DT O
price NN O
control NN O
however RB O
a DT O
strict JJ O
watch NN O
would MD O
be VB O
kept VBN O
on IN O
the DT O
movement NN O
of IN O
prices NNS O
as IN O
it PRP O
is VBZ O
expected VBN O
that IN O
their PRP$ O
prices NNS O
would MD O
be VB O
kept VBN O
in IN O
check NN O
by IN O
the DT O
forces NNS O
of IN O
market NN O
competition NN O
the DT O
government NN O
may MD O
determine VB O
the DT O
ceiling NN O
levels NNS O
beyond IN O
which WDT O
increase NN O
in IN O
prices NNS O
would MD O
not RB O
be VB O
permissible JJ O
iv JJ O
government NN O
will MD O
keep VB O
a DT O
close JJ O
watch NN O
on IN O
the DT O
prices NNS O
of IN O
medicines NNS O
which WDT O
are VBP O
taken VBN O
out IN O
of IN O
price NN O
control NN O
in IN O
case NN O
the DT O
prices NNS O
of IN O
these DT O
medicines NNS O
rise NN O
unreasonably RB O
the DT O
government NN O
would MD O
take VB O
appropriate JJ O
measures NNS O
including VBG O
reclaim NN O
of IN O
price NN O
control NN O
v NN O
for IN O
applying VBG O
the DT O
above NN O
criteria NN O
to TO O
start VB O
with IN O
the DT O
basis NN O
would MD O
be VB O
the DT O
data NNS O
upto RB O
31st CD O
march NN O
1990 CD O
collected VBD O
for IN O
the DT O
exercise NN O
of IN O
the DT O
review NN O
of IN O
the DT O
drug NN O
policy NN O
the DT O
updating NN O
of IN O
the DT O
data NNS O
will MD O
be VB O
done VBN O
by IN O
the DT O
national JJ O
pharmaceutical JJ O
pricing NN O
authority NN O
as IN O
detailed VBN O
in IN O
para NN O
2274i CD O
3 CD O
the DT O
central JJ O
theme NN O
of IN O
the DT O
arguments NNS O
is VBZ O
that IN O
the DT O
norms NNS O
set VBD O
out RP O
in IN O
sub JJ O
paras NNS O
i VBP O
ii VBP O
iii NNS O
have VBP O
not RB O
been VBN O
adhered VBN O
to TO O
by IN O
the DT O
government NN O
while IN O
framing VBG O
the DT O
first JJ O
schedule NN O
to TO O
dpco VB O
in IN O
purported JJ O
implementation NN O
of IN O
the DT O
drug NN O
policy NN O
there EX O
was VBD O
either DT O
deviation NN O
from IN O
the DT O
criteria NNS O
set VBN O
out RP O
or CC O
there EX O
was VBD O
no DT O
scientific JJ O
or CC O
rational JJ O
assessment NN O
of IN O
the DT O
factors NNS O
relevant VBP O
to TO O
the DT O
norms NNS O
most JJS O
of IN O
the DT O
arguments NNS O
centered VBD O
round IN O
the DT O
interpretation NN O
of IN O
the DT O
three CD O
clauses NNS O
in IN O
para NN O
2272 CD O
an DT O
exercise NN O
which WDT O
is VBZ O
usually RB O
associated VBN O
with IN O
the DT O
construction NN O
of IN O
statutes NNS O
the DT O
sum NN O
and CC O
substance NN O
of IN O
the DT O
arguments NNS O
on IN O
behalf NN O
of IN O
the DT O
respondents NNS O
is VBZ O
that IN O
the DT O
seven CD O
bulk NN O
drugs NNS O
get VBP O
excluded VBN O
from IN O
the DT O
span NN O
of IN O
control NN O
under IN O
one CD O
or CC O
more JJR O
norms NNS O
spelt VBD O
out RP O
in IN O
para NN O
2272 CD O
whereas IN O
the DT O
stand NN O
of IN O
the DT O
appellants NNS O
is VBZ O
that IN O
the DT O
concerned JJ O
bulk NN O
drugs NNS O
were VBD O
included VBN O
in IN O
the DT O
schedule NN O
only RB O
after IN O
being VBG O
satisfied VBD O
that IN O
they PRP O
came VBD O
within IN O
the DT O
ambit NN O
of IN O
price NN O
control NN O
criteria NN O
it PRP O
is VBZ O
also RB O
the DT O
contention NN O
of IN O
the DT O
appellant NN O
that IN O
the DT O
government NN O
s NN O
decision NN O
to TO O
bring VB O
these DT O
important JJ O
bulk NN O
drugs NNS O
within IN O
price NN O
control NN O
is VBZ O
in IN O
accordance NN O
with IN O
the DT O
objectives NNS O
underlying VBG O
in IN O
section NN O
3 CD O
of IN O
the DT O
essential JJ O
commodities NNS O
act VBP O
particularly RB O
the DT O
interests NNS O
of IN O
consumers NNS O
every DT O
attempt NN O
was VBD O
made VBN O
to TO O
examine VB O
the DT O
facts NNS O
and CC O
figures NNS O
by IN O
an DT O
expert JJ O
group NN O
of IN O
the DT O
standing VBG O
committee NN O
keeping VBG O
in IN O
view NN O
the DT O
prescribed NN O
norms NNS O
in IN O
drug NN O
policy NN O
it PRP O
is VBZ O
pointed VBN O
out RP O
that IN O
the DT O
high JJ O
court NN O
cannot MD O
go RB O
into VB O
the IN O
intricacies DT O
of NNS O
price IN O
fixation NN O
under NN O
article IN O
226 NN O
of CD O
the IN O
constitution DT O
or NN O
sit CC O
in NN O
judgment IN O
over NN O
the IN O
exercise DT O
done NN O
by VBN O
experts IN O
41 NNS O
it CD O
is PRP O
axiomatic VBZ O
that JJ O
the IN O
contents DT O
of NNS O
a IN O
policy DT O
documents NN O
cannot NNS O
be MD O
read RB O
and VB O
interpreted VBN O
as CC O
statutory VBN O
provisions IN O
too JJ O
much NNS O
of RB O
legalism JJ O
cannot IN O
be NN O
imported MD O
in RB O
understanding VB O
the VBN O
scope IN O
and VBG O
meaning DT O
of NN O
the CC O
clauses NN O
contained IN O
in DT O
policy NNS O
formulations VBN O
at IN O
the NN O
same NNS O
time IN O
the DT O
central JJ O
government NN O
which DT O
combines JJ O
the NN O
dual WDT O
role VBZ O
of DT O
policy JJ O
maker NN O
and IN O
the NN O
delegate NN O
of CC O
legislative DT O
power NN O
cannot IN O
at JJ O
its NN O
sweet MD O
will RB O
and IN O
pleasure PRP$ O
give NN O
a MD O
go CC O
bye VB O
to VB O
the DT O
policy NN O
guidelines NN O
evolved TO O
by DT O
itself NN O
in NNS O
the VBN O
matter IN O
of PRP O
selection IN O
of DT O
drugs NN O
for IN O
price NN O
control IN O
the NNS O
government IN O
itself NN O
stressed NN O
the DT O
need NN O
to PRP O
evolve VBD O
and DT O
adopt NN O
transparent TO O
criteria VB O
to CC O
be VB O
applied JJ O
across NNS O
the TO O
board VB O
so VBN O
as IN O
to DT O
minimize NN O
the RB O
scope IN O
for TO O
subjective VB O
approach DT O
and NN O
therefore IN O
came JJ O
forward NN O
with CC O
specific RB O
criteria VBD O
it RB O
is IN O
nobody JJ O
s NNS O
case PRP O
that VBZ O
for JJ O
any JJ O
good NN O
reasons IN O
the IN O
policy DT O
or JJ O
norms NNS O
have DT O
been NN O
changed CC O
or NNS O
became VBP O
impracticable VBN O
of VBN O
compliance CC O
that VBD O
being JJ O
the IN O
case NN O
the IN O
government VBG O
exercising DT O
its NN O
delegated DT O
legislative NN O
power VBG O
should PRP$ O
make JJ O
a JJ O
real NN O
and MD O
earnest VB O
attempt DT O
to JJ O
apply CC O
the JJS O
criteria NN O
laid TO O
down VB O
by DT O
itself NN O
the VBD O
delegated RB O
legislation IN O
that PRP O
follows DT O
the JJ O
policy NN O
formulation WDT O
should VBZ O
be DT O
broadly NN O
and NN O
substantially MD O
in VB O
conformity RB O
with CC O
that RB O
policy IN O
otherwise NN O
it IN O
would DT O
be NN O
vulnerable IN O
to PRP O
attack MD O
on VB O
the JJ O
ground TO O
of VB O
arbitrariness IN O
resulting DT O
in NN O
violation IN O
of NN O
article VBG O
14 IN O
42 NN O
in IN O
indian NN O
express CD O
newspapers CD O
v IN O
union JJ O
of NN O
india NNS O
the VBP O
grounds NN O
on IN O
which VBG O
subordinate DT O
legislation NNS O
can IN O
be WDT O
questioned JJ O
were NN O
outlined MD O
by VB O
this VBN O
court VBD O
es VBN O
venkataramiah IN O
j DT O
observed NN O
thus VBZ O
a JJ O
piece NN O
of VBD O
subordinate RB O
legislation DT O
does NN O
not IN O
carry JJ O
the NN O
same VBZ O
degree RB O
of VB O
immunity DT O
which JJ O
is NN O
enjoyed IN O
by NN O
a WDT O
statute VBZ O
passed VBN O
by IN O
a DT O
competent NN O
legislature VBN O
subordinate IN O
legislation DT O
may JJ O
be NN O
questioned JJ O
on NN O
any MD O
of VB O
the VBN O
ground IN O
on DT O
which IN O
plenary DT O
legislation NN O
is IN O
questioned WDT O
in JJ O
addition NN O
it VBZ O
may VBN O
also IN O
be NN O
questioned PRP O
on MD O
the RB O
ground VB O
that VBN O
it IN O
does DT O
not NN O
conform IN O
to PRP O
the VBZ O
statute RB O
under VB O
which TO O
it DT O
is NN O
made IN O
it WDT O
may PRP O
also VBZ O
be VBN O
questioned PRP O
on MD O
the RB O
ground VB O
that VBN O
it IN O
is DT O
unreasonable NN O
unreasonable IN O
not PRP O
in VBZ O
the JJ O
sense JJ O
of RB O
not IN O
being DT O
reasonable NN O
but IN O
in RB O
the VBG O
sense JJ O
that CC O
it IN O
is DT O
manifestly NN O
arbitrary IN O
in PRP O
england VBZ O
the RB O
judges JJ O
would IN O
say VBP O
parliament DT O
never NNS O
intended MD O
authority VB O
to NN O
make RB O
such VBN O
rules NN O
they TO O
are VB O
unreasonable JJ O
and NNS O
ultra PRP O
vires VBP O
43 JJ O
true CC O
the JJ O
breach NNS O
of CD O
policy JJ O
decision DT O
by NN O
itself IN O
is NN O
not NN O
a IN O
ground PRP O
to VBZ O
invalidate RB O
delegated DT O
legislation NN O
but TO O
in VB O
a JJ O
case NN O
like CC O
this IN O
the DT O
inevitable NN O
fallout IN O
of DT O
the DT O
breach JJ O
of NN O
policy IN O
decision DT O
which NN O
the IN O
government NN O
itself NN O
treated WDT O
as DT O
a NN O
charter PRP O
for VBD O
the IN O
resultant DT O
legislation NN O
is IN O
to DT O
leave JJ O
an NN O
imprint VBZ O
of TO O
arbitrariness VB O
on DT O
the NN O
legislation IN O
when NN O
the IN O
selection DT O
or NN O
classification WRB O
of DT O
certain NN O
drugs CC O
is NN O
involved IN O
for JJ O
the NNS O
purpose VBZ O
of VBN O
price IN O
control DT O
such NN O
selection IN O
or NN O
classification NN O
should JJ O
be NN O
on CC O
rational NN O
basis MD O
and VB O
cannot IN O
be JJ O
strikingly NN O
arbitrary CC O
no MD O
doubt RB O
in VB O
such RB O
matters JJ O
wide DT O
latitude NN O
is IN O
conceded JJ O
to NNS O
the JJ O
legislature NN O
or VBZ O
its VBN O
delegate TO O
broadly DT O
the NN O
subordinate CC O
law PRP$ O
making NN O
authority RB O
is DT O
guided NN O
by NN O
the VBG O
policy NN O
and VBZ O
objectives VBN O
of IN O
primary DT O
legislation NN O
disclosed CC O
by NNS O
preamble IN O
and JJ O
other NN O
provisions VBN O
the IN O
delegated JJ O
legislation CC O
need JJ O
not NNS O
be DT O
modelled JJ O
on NN O
a MD O
set RB O
pattern VB O
or VBN O
pre IN O
fixed DT O
guidelines NN O
however NN O
where CC O
the NN O
delegate VBN O
goes NNS O
a RB O
step WRB O
further DT O
draws NN O
up VBZ O
and DT O
announces NN O
a RB O
rational VBZ O
policy RP O
in CC O
keeping VBZ O
with DT O
the JJ O
purposes NN O
of IN O
enabling VBG O
legislation IN O
and DT O
even NNS O
lays IN O
down VBG O
specific NN O
criteria CC O
to RB O
promote NNS O
the RP O
policy JJ O
the NNS O
criteria TO O
so VB O
evolved DT O
become NN O
the DT O
guide NNS O
posts RB O
for VBD O
its VB O
legislative DT O
action JJ O
in NNS O
that IN O
sense PRP$ O
its JJ O
freedom NN O
of IN O
classification DT O
will NN O
be PRP$ O
regulated NN O
by IN O
the NN O
self MD O
evolved VB O
criteria VBN O
and IN O
there DT O
should NN O
be VBD O
demonstrable NNS O
justification CC O
for EX O
deviating MD O
therefrom VB O
though JJ O
exactitude NN O
and IN O
meticulous VBG O
conformance NN O
is IN O
not NN O
what CC O
is JJ O
required NN O
it VBZ O
is RB O
not WP O
open VBZ O
to VBN O
the PRP O
government VBZ O
to RB O
go JJ O
hay TO O
wire DT O
and NN O
flout TO O
or VB O
debilitate JJ O
the NN O
set CC O
norms NN O
either CC O
by VB O
giving DT O
distorted NN O
meaning NNS O
to CC O
them IN O
or VBG O
by JJ O
disregarding NN O
the TO O
very PRP O
facts CC O
and IN O
factors VBG O
which DT O
it JJ O
professed NNS O
to CC O
take NNS O
into WDT O
account PRP O
in VBD O
the TO O
interest VB O
of IN O
transparency NN O
and IN O
objectivity DT O
otherwise NN O
the IN O
legislative NN O
act CC O
of NN O
the RB O
delegate DT O
in JJ O
choosing NN O
some IN O
drugs DT O
for NN O
price IN O
control VBG O
while DT O
leaving NNS O
others IN O
will NN O
attract NN O
the IN O
wrath VBG O
of NNS O
article MD O
14 VB O
that DT O
is NN O
why IN O
the NN O
union CD O
of WDT O
india VBZ O
has WRB O
taken DT O
the NN O
stand IN O
throughout NN O
that VBZ O
it VBN O
stood DT O
by NN O
the IN O
policy IN O
while PRP O
framing VBD O
the IN O
legislation DT O
and NN O
that IN O
there VBG O
was DT O
every NN O
endeavour CC O
to IN O
apply EX O
the VBD O
criteria DT O
spelt NN O
out TO O
in VB O
the DT O
drug NNS O
policy VBD O
of RP O
1994 IN O
before DT O
including NN O
the NN O
drugs IN O
in CD O
question IN O
in VBG O
the DT O
first NNS O
schedule IN O
the NN O
correctness IN O
of DT O
this JJ O
contention NN O
should DT O
of NN O
course IN O
be DT O
examined NN O
51 MD O
with IN O
this NN O
prologue VB O
let VBN O
us CD O
proceed IN O
to DT O
analyze NN O
the VBD O
three PRP O
relevant VB O
criteria TO O
in VB O
the DT O
drug CD O
policy JJ O
according NNS O
to IN O
the DT O
first NN O
criteria NN O
for VBG O
bringing TO O
the DT O
drugs JJ O
under NNS O
the IN O
price VBG O
control DT O
the NNS O
minimum IN O
annual DT O
turnover NN O
of NN O
the DT O
drug JJ O
should JJ O
be NN O
400 IN O
lacs DT O
however NN O
this MD O
requirement VB O
is CD O
qualified JJ O
by RB O
and DT O
subject NN O
to VBZ O
the VBN O
criteria IN O
laid CC O
down JJ O
in TO O
ii DT O
iii NN O
where VBD O
a RB O
monopoly IN O
situation NN O
prevails NN O
in WRB O
respect DT O
of NN O
any NN O
bulk VBZ O
drug IN O
the NN O
minimum IN O
annual DT O
turnover JJ O
requirement NN O
gets DT O
reduced JJ O
to JJ O
100 NN O
lacs NN O
the VBZ O
monopoly VBN O
situation TO O
is CD O
deemed PDT O
to DT O
exist NN O
where NN O
there VBZ O
is VBN O
a TO O
single VB O
formulator WRB O
commanding EX O
90 VBZ O
or DT O
more JJ O
market NN O
share VBG O
in CD O
the CC O
retail JJR O
trade NN O
as NN O
per IN O
org DT O
data JJ O
according NN O
to IN O
the IN O
3rd NN O
criterion NNS O
even VBG O
if TO O
minimum DT O
annual CD O
turnover NN O
exceeds RB O
400 IN O
lacs JJ O
the JJ O
drug NN O
will VBZ O
be CD O
kept IN O
outside DT O
price NN O
control MD O
in VB O
case VBN O
there JJ O
is NN O
sufficient NN O
market IN O
competition NN O
the EX O
yardstick VBZ O
rhea JJ O
assessing NN O
whether NN O
there DT O
is NN O
sufficient NN O
market VBG O
competition IN O
according EX O
to VBZ O
clause JJ O
iii NN O
is NN O
that VBG O
there TO O
are NN O
at NN O
least VBZ O
five IN O
producers EX O
of VBP O
the IN O
particular JJS O
bulk CD O
drug NNS O
and IN O
at DT O
least JJ O
ten JJ O
formulators NN O
and CC O
none IN O
of JJS O
them JJ O
have NNS O
more CC O
than NN O
40 IN O
market PRP O
share VBP O
in JJR O
the IN O
retail CD O
trade NN O
as NN O
per IN O
org DT O
data JJ O
the NN O
said IN O
criteria IN O
have NN O
to NNS O
be DT O
worked VBD O
out NNS O
with VBP O
reference TO O
to VB O
the VBN O
data RP O
available IN O
upto NN O
31st TO O
march DT O
1990 NNS O
which JJ O
means JJ O
the CD O
relevant NN O
facts CD O
and WDT O
figures VBZ O
relating DT O
to JJ O
financial NNS O
year CC O
1989 NNS O
90 VBG O
have TO O
to JJ O
be NN O
taken CD O
into CD O
account VBP O
this TO O
is VB O
not VBN O
in IN O
dispute NN O
52 DT O
already VBZ O
noted RB O
there IN O
is NN O
no CD O
quarrel RB O
about VBN O
the EX O
criteria VBZ O
that DT O
has NN O
been IN O
laid DT O
down NNS O
it WDT O
is VBZ O
not VBN O
the VBN O
case IN O
of PRP O
the VBZ O
union RB O
of DT O
india NN O
that IN O
any DT O
different NN O
criteria IN O
had NN O
been IN O
applied DT O
while JJ O
promulgating NNS O
the VBD O
dpco VBN O
of VBN O
1995 IN O
the VBG O
controversy DT O
revolves NN O
round IN O
its CD O
actual DT O
application NN O
or VBZ O
methodology RP O
of PRP$ O
working JJ O
out NN O
the CC O
criteria NN O
what IN O
is VBG O
the RP O
annual DT O
turnover NNS O
made WP O
up VBZ O
of DT O
in JJ O
other NN O
words VBD O
how RB O
to IN O
work IN O
out JJ O
the NNS O
turnover WRB O
figures TO O
is VB O
there RP O
sufficient DT O
market NN O
competition NNS O
as VBZ O
contemplated RB O
by JJ O
clause NN O
iii NN O
it IN O
is VBN O
with IN O
reference NN O
to NN O
these PRP O
two VBZ O
aspects IN O
that NN O
the TO O
government DT O
s CD O
stand NNS O
has IN O
not DT O
been NN O
accepted NN O
and NN O
the VBZ O
writ RB O
petitioner VBN O
s VBN O
contention CC O
found DT O
its NN O
acceptance NN O
by JJ O
the NN O
high VBD O
court PRP$ O
53 NN O
first IN O
we DT O
shall JJ O
take NN O
up CD O
the JJ O
issue PRP O
of MD O
annual VB O
turnover RP O
the DT O
stand NN O
of IN O
the JJ O
appellant IN O
as DT O
discernible NN O
from IN O
the DT O
affidavits NN O
on IN O
record JJ O
sworn IN O
to DT O
by NNS O
the IN O
officials NN O
of VBN O
the TO O
department IN O
of DT O
chemicals NNS O
and IN O
petrochemicals DT O
government NN O
of IN O
india NNS O
is CC O
that NNS O
the NN O
turnover IN O
of NN O
bulk VBZ O
drug IN O
ought DT O
not NN O
to IN O
be JJ O
mixed NN O
up MD O
with RB O
retail TO O
sale VB O
data VBN O
of RP O
the IN O
formulations JJ O
of NN O
that NNS O
bulk IN O
drug DT O
in NNS O
other IN O
words DT O
the JJ O
retail NN O
sale IN O
data JJ O
pertains NNS O
to DT O
formulations JJ O
of NN O
bulk NNS O
drug NNS O
and TO O
not NNS O
to IN O
the JJ O
bulk NN O
drug CC O
itself RB O
the TO O
broad DT O
manner NN O
in NN O
which PRP O
the DT O
turnover JJ O
has NN O
been IN O
assessed WDT O
is DT O
indicated NN O
in VBZ O
paragraph VBN O
8 VBN O
of VBZ O
the VBN O
rejoinder IN O
affidavit NN O
filed CD O
in IN O
slps DT O
it NN O
is NN O
stated VBN O
that IN O
the NN O
expert PRP O
group VBZ O
of VBN O
the IN O
standing DT O
committee JJ O
which NN O
went IN O
into DT O
the VBG O
whole NN O
issue WDT O
of VBD O
exclusion IN O
inclusion DT O
of JJ O
drugs NN O
under IN O
price JJ O
control NN O
took IN O
the NNS O
date IN O
for NN O
turnover NN O
of VBD O
the DT O
bulk NN O
drugs IN O
comprising NN O
of IN O
the DT O
value NN O
of NNS O
its VBG O
total IN O
production DT O
in NN O
the IN O
country PRP$ O
and JJ O
value NN O
of IN O
weighted DT O
average NN O
of CC O
landed NN O
cost IN O
of JJ O
total NN O
imports IN O
into JJ O
the NN O
country IN O
as JJ O
the NNS O
basis IN O
for DT O
viewing NN O
the IN O
price DT O
scenario NN O
from IN O
different VBG O
points DT O
of NN O
view NN O
it IN O
is JJ O
then NNS O
stated IN O
in NN O
paragraph PRP O
10 VBZ O
in RB O
the VBN O
further IN O
respectful NN O
submission CD O
of IN O
the DT O
petitioner JJ O
the JJ O
intent NN O
behind IN O
using DT O
the NN O
said DT O
word NN O
turnover IN O
has VBG O
been DT O
to VBD O
determine NN O
the NN O
extent VBZ O
of VBN O
usage TO O
of VB O
a DT O
bulk NN O
drug IN O
in NN O
the IN O
country DT O
emphasis JJ O
supplied NN O
this IN O
was DT O
the NN O
measure NN O
adopted VBD O
by DT O
the VBD O
expert DT O
group NN O
in VBN O
case IN O
of DT O
each NN O
bulk NN O
drug IN O
by NN O
taking IN O
into DT O
account NN O
the NN O
aggregate IN O
of VBG O
its IN O
total NN O
imports DT O
into NN O
the IN O
country PRP$ O
and JJ O
its NNS O
total IN O
indigenous DT O
production NN O
in CC O
the PRP$ O
country JJ O
this JJ O
has NN O
been IN O
the DT O
connotation NN O
of DT O
the VBZ O
word VBN O
turnover DT O
at NN O
various IN O
levels DT O
throughout NN O
the NN O
deliberations IN O
and JJ O
in NNS O
implementation IN O
of DT O
the NNS O
policy CC O
through IN O
dpco NN O
1995 IN O
and DT O
was NN O
never IN O
confined NN O
to CD O
the CC O
narrow VBD O
connotation RB O
of VBN O
the TO O
word DT O
sales JJ O
turnover NN O
in IN O
short DT O
it NN O
is NNS O
submitted NN O
vide IN O
paragraph JJ O
13 PRP O
that VBZ O
the VBN O
value IN O
of NN O
total CD O
production IN O
plus DT O
imports NN O
of IN O
the JJ O
bulk NN O
drug CC O
in NNS O
the IN O
country DT O
determines JJ O
the NN O
annual IN O
turnover DT O
for NN O
the VBZ O
purpose DT O
of JJ O
clauses NN O
i IN O
ii DT O
of NN O
para IN O
2272 NNS O
as JJ O
a NN O
corollary IN O
to NN O
this CD O
stand IN O
the DT O
contention NN O
advanced TO O
on DT O
behalf VB O
of DT O
the NN O
union VBD O
of IN O
india NN O
is IN O
that DT O
export NN O
sales IN O
could NN O
also VBZ O
be IN O
taken NN O
into NNS O
account MD O
in RB O
arriving VB O
at VBN O
the IN O
annual NN O
turnover IN O
according VBG O
to IN O
the DT O
respondents JJ O
writ NN O
petitioners VBG O
the TO O
annual DT O
turnover NNS O
could WDT O
only NNS O
mean DT O
sales JJ O
of NN O
bulk MD O
drug RB O
within VB O
the NNS O
country IN O
either JJ O
in NN O
the IN O
same DT O
form NN O
or CC O
by IN O
way DT O
of JJ O
formulations NN O
and CC O
it IN O
has NN O
nothing IN O
to NNS O
do CC O
with PRP O
export VBZ O
sales NN O
the TO O
entirety VB O
of IN O
production NN O
and NNS O
imports DT O
cannot NN O
be IN O
regarded NN O
as CC O
turnover NNS O
it MD O
is RB O
submitted VB O
by VBN O
the IN O
respondents NN O
that PRP O
the VBZ O
bulk VBN O
drugs IN O
are DT O
sold NNS O
mostly IN O
in DT O
the NN O
form NNS O
of VBP O
formulations VBN O
and RB O
the IN O
quantities DT O
of NN O
bulk IN O
drugs NNS O
utilized CC O
in DT O
such NNS O
formulations IN O
are NN O
given NNS O
in VBN O
org IN O
data JJ O
from NNS O
this VBP O
the VBN O
bulk IN O
drug JJ O
turnover NNS O
can IN O
be DT O
easily DT O
ascertained JJ O
the NN O
sales NN O
of MD O
the VB O
bulk RB O
drugs VBN O
as DT O
such NNS O
to IN O
the DT O
institutions NN O
etc NNS O
will IN O
be JJ O
negligible TO O
ie DT O
about NNS O
15 VBP O
as MD O
per VB O
the JJ O
certificate NN O
issued RB O
by CD O
org IN O
in IN O
one DT O
of NN O
the VBN O
cases IN O
it NN O
is IN O
therefore CD O
commented IN O
that DT O
the NNS O
contention PRP O
that VBZ O
the RB O
org VBN O
data IN O
does DT O
not NN O
afford IN O
the DT O
basis JJ O
for NN O
ascertaining VBZ O
the RB O
annual VB O
turnover DT O
of NN O
the IN O
bulk VBG O
drug DT O
is JJ O
untenable NN O
54 IN O
the DT O
high JJ O
court NN O
substantially VBZ O
agreeing JJ O
with CD O
the DT O
contentions JJ O
of NN O
the RB O
respondents VBG O
writ IN O
petitioners DT O
held NNS O
that IN O
the DT O
expression NNS O
turnover VBP O
occurring NNS O
in VBD O
drugs IN O
policy DT O
can NN O
only NN O
mean VBG O
domestic IN O
sales NNS O
figures NN O
and MD O
nothing RB O
else VB O
export JJ O
sales NNS O
cannot NNS O
be CC O
included NN O
within RB O
the NN O
ambit NNS O
of MD O
turnover RB O
the VB O
high VBN O
court IN O
observed DT O
that NN O
the IN O
concepts NN O
of DT O
turnover JJ O
and NN O
market VBD O
share IN O
are DT O
interrelated NNS O
and IN O
inter NN O
dependent CC O
the NN O
expression NN O
turnover VBP O
if VBN O
interpreted CC O
in JJ O
a NN O
contextual DT O
and NN O
purposive NN O
manner IN O
would VBN O
not IN O
include DT O
exports JJ O
the CC O
extent JJ O
of NN O
usage MD O
of RB O
the VB O
bulk NNS O
drug DT O
in NN O
the IN O
country NN O
would IN O
be DT O
determinative JJ O
of NN O
turnover IN O
by DT O
taking NN O
the MD O
export VB O
sale JJ O
figures IN O
and NN O
the IN O
value VBG O
of DT O
entire NN O
production NN O
of NNS O
bulk CC O
drugs DT O
into NN O
account IN O
the JJ O
central NN O
government IN O
had NN O
acted NNS O
contrary IN O
to NN O
its DT O
own JJ O
guidelines NN O
contained VBD O
in VBN O
drug JJ O
policy TO O
1994 PRP$ O
the JJ O
high NNS O
court VBN O
then IN O
proceeded NN O
to NN O
discuss CD O
whether DT O
each JJ O
of NN O
the RB O
drugs VBD O
concerned TO O
could VB O
be IN O
brought DT O
within IN O
the DT O
purview NNS O
of VBN O
dcpo MD O
1995 VB O
and VBN O
answered IN O
that DT O
question NN O
in IN O
favour NN O
of CD O
the CC O
writ VBD O
petitioners DT O
55 NN O
before IN O
proceeding NN O
further IN O
we DT O
may NN O
notice NNS O
that CD O
the IN O
national VBG O
pharmaceutical JJ O
pricing PRP O
authority MD O
nppa VB O
constituted IN O
by DT O
the JJ O
government JJ O
of NN O
india NN O
considered RB O
the VBN O
representation IN O
of DT O
bulk NN O
drugs IN O
manufacturers NN O
association VBN O
bdma DT O
on NN O
the IN O
subject NN O
of NNS O
inclusion NNS O
exclusion VBP O
of NN O
drugs IN O
under DT O
dpco NN O
the IN O
nppa NN O
passed NN O
a IN O
reasoned NNS O
order IN O
rejected NN O
the DT O
representation NN O
on VBD O
dt DT O
641998 VBN O
in NN O
that VBD O
order DT O
the NN O
issues IN O
raised NN O
by CD O
bdma IN O
regarding DT O
exclusion NN O
of DT O
six NNS O
out VBN O
of IN O
eight NN O
drugs VBG O
with NN O
which IN O
we CD O
are IN O
concerned IN O
were CD O
considered NNS O
by IN O
the WDT O
said PRP O
authority VBP O
there VBN O
was VBD O
however VBN O
no IN O
consideration DT O
as VBD O
regards NN O
two EX O
drugs VBD O
namely RB O
doxycycline DT O
and NN O
glipizide IN O
probably NNS O
because CD O
the NNS O
representation RB O
did VBP O
not CC O
cover NN O
those RB O
two IN O
drugs DT O
56 NN O
before VBD O
we RB O
take VB O
up DT O
the CD O
issue NNS O
of CD O
export IN O
sales PRP O
it VBP O
is RP O
necessary DT O
to NN O
understand IN O
the NN O
true NNS O
import PRP O
and VBZ O
expanse JJ O
of TO O
the VB O
expression DT O
turnover JJ O
occurring NN O
in CC O
clause NN O
i IN O
of DT O
para NN O
2272 NN O
of VBG O
the IN O
drug NN O
policy NN O
1994 IN O
what NN O
is CD O
the IN O
turnover DT O
contemplated NN O
by NN O
the CD O
said WP O
paragraph VBZ O
can DT O
it NN O
be VBN O
equated IN O
to DT O
the VBD O
value NN O
of MD O
imported PRP O
bulk VB O
drug VBN O
and TO O
its DT O
production NN O
as IN O
contended VBN O
by JJ O
the NN O
appellant CC O
or PRP$ O
should NN O
it IN O
be VBN O
equated IN O
to DT O
the NN O
actual CC O
sales MD O
within PRP O
the VB O
country VBN O
should TO O
the DT O
export JJ O
sales NNS O
be IN O
included DT O
in NN O
turnover MD O
these DT O
are NN O
the NNS O
questions VB O
to VBN O
which IN O
this NN O
court DT O
has VBP O
to DT O
address NNS O
itself TO O
57 WDT O
turnover DT O
in NN O
its VBZ O
ordinary TO O
sense VB O
connotes PRP O
amount CD O
of NN O
business IN O
usually PRP$ O
expressed JJ O
in NN O
terms VBZ O
of NN O
gross IN O
revenue NN O
transacted RB O
during VBN O
a IN O
specified NNS O
period IN O
vide JJ O
collins NN O
dictionary VBD O
broadly IN O
speaking DT O
it JJ O
represents NN O
the IN O
value NNS O
of JJ O
the RB O
goods VBG O
or PRP O
services VBZ O
sold DT O
or NN O
supplied IN O
during DT O
a NNS O
period CC O
of NNS O
time VBN O
the CC O
amount VBN O
of IN O
money DT O
turned NN O
over IN O
or NN O
drawn DT O
in NN O
a IN O
business NN O
during VBN O
certain RP O
period CC O
is VBN O
another IN O
shade DT O
of NN O
meaning IN O
we JJ O
need NN O
not VBZ O
refer DT O
to NN O
the IN O
definition VBG O
of PRP O
turnover VBP O
in RB O
sales VB O
tax TO O
and DT O
other NN O
fiscal IN O
enactments NN O
reliance IN O
on NNS O
which NN O
was CC O
placed JJ O
by JJ O
some NNS O
of NN O
the IN O
learned WDT O
counsel VBD O
as VBN O
they IN O
are DT O
not IN O
quite DT O
relevant JJ O
for NN O
the IN O
purpose PRP O
of VBP O
understanding RB O
the RB O
expression JJ O
turnover IN O
occurring DT O
in NN O
a IN O
policy VBG O
document DT O
nor NN O
should NN O
we VBG O
seek IN O
any DT O
assistance NN O
from NN O
the CC O
definition MD O
of PRP O
sale VB O
turnover DT O
occurring NN O
in IN O
dpco DT O
in NN O
a IN O
different NN O
context NN O
and VBG O
for IN O
a NN O
different IN O
purpose DT O
going JJ O
by NN O
its CC O
ordinary IN O
meaning DT O
and JJ O
the NN O
way VBG O
in IN O
which PRP$ O
it JJ O
is NN O
commonly CC O
understood DT O
in NN O
trade IN O
and WDT O
commerce PRP O
it VBZ O
is RB O
difficult JJ O
to IN O
equate NN O
turnover CC O
to NN O
the PRP O
value VBZ O
of JJ O
stock TO O
acquired VB O
either NN O
by TO O
means DT O
of NN O
imports IN O
or NN O
production VBD O
for CC O
instance IN O
the NNS O
entire IN O
stock NNS O
in CC O
trade NN O
say IN O
lying NN O
in DT O
a JJ O
godown NN O
and IN O
not NN O
circulated VBP O
in VBG O
business IN O
cannot DT O
be NN O
regarded CC O
as RB O
turnover VBN O
even IN O
giving NN O
broadest MD O
meaning RB O
to VB O
the VBN O
expression IN O
turnover NN O
the RB O
reasoning VBG O
which JJS O
could NN O
be TO O
spelt DT O
out NN O
from IN O
the DT O
order NN O
passed WDT O
by MD O
nppa VB O
referred VBN O
to RP O
supra IN O
and DT O
in NN O
the VBN O
counter IN O
affidavits NN O
filed VBN O
by TO O
the VB O
appellants CC O
that IN O
indigenous DT O
production NN O
plus NNS O
imports VBN O
furnishes IN O
an DT O
indicia NNS O
of WDT O
the JJ O
total NN O
business CC O
in NNS O
the NNS O
country DT O
in NN O
relation IN O
to DT O
a JJ O
particular NN O
bulk IN O
drug DT O
cannot NN O
be IN O
accepted NN O
it TO O
is DT O
only JJ O
what JJ O
is NN O
sold MD O
out RB O
and VB O
marketed VBN O
that PRP O
could VBZ O
be RB O
legitimately WP O
regarded VBZ O
as VBN O
turnover RP O
of CC O
the VBD O
specified DT O
drug MD O
it VB O
may RB O
be VBN O
that IN O
in NN O
the IN O
absence DT O
of VBN O
availability NN O
of PRP O
reliable MD O
data VB O
regarding IN O
sales IN O
the DT O
import NN O
value IN O
and NN O
production IN O
value JJ O
could NNS O
be VBG O
the NNS O
basis DT O
to NN O
estimate NN O
the CC O
sale NN O
value NN O
after MD O
giving VB O
due DT O
allowance NN O
to TO O
various VB O
factors DT O
such NN O
as NN O
wastage IN O
unsold VBG O
stocks JJ O
etc NN O
but TO O
treating JJ O
the NNS O
turnover JJ O
as IN O
nothing NN O
but JJ O
the NNS O
value VBP O
of CC O
stock VBG O
produced DT O
or NN O
imported IN O
during NN O
a CC O
given DT O
period NN O
will IN O
be NN O
doing VBD O
violence CC O
to VBN O
the IN O
ordinarily DT O
accepted VBN O
meaning NN O
of MD O
the VB O
expression VBG O
turnover NN O
there TO O
can DT O
be RB O
no JJ O
presumption NN O
that IN O
the DT O
entire NN O
stock IN O
of EX O
bulk MD O
drug VB O
produced DT O
or NN O
imported IN O
during DT O
the JJ O
year NN O
had IN O
been JJ O
sold NN O
out VBD O
during CC O
that VBN O
year IN O
either DT O
in NN O
the VBD O
form VBN O
of VBN O
formulations RP O
or IN O
otherwise DT O
however NN O
we RB O
would IN O
like DT O
to NN O
make IN O
it NNS O
clear CC O
that RB O
the RB O
production PRP O
and MD O
import VB O
statistics TO O
are VB O
not PRP O
altogether JJ O
irrelevant IN O
they DT O
are NN O
relevant CC O
in NN O
the NNS O
sense VBP O
that RB O
they RB O
furnish JJ O
some PRP O
basis VBP O
for JJ O
estimating IN O
the DT O
sales NN O
when IN O
there PRP O
is VBP O
no DT O
other NN O
reliable IN O
and VBG O
comprehensive DT O
data NNS O
of WRB O
sales EX O
available VBZ O
58 DT O
the JJ O
question JJ O
whether CC O
export JJ O
sales NNS O
should IN O
also NNS O
be JJ O
taken CD O
into DT O
account NN O
in IN O
computing NN O
the NNS O
annual MD O
turnover RB O
needs VB O
to VBN O
be IN O
discussed NN O
now IN O
there VBG O
can DT O
be JJ O
no NN O
doubt NNS O
that TO O
the VB O
meaning VBN O
of RB O
the EX O
expression MD O
turnover VB O
either DT O
in NN O
its IN O
ordinary DT O
or NN O
legal IN O
sense DT O
includes NN O
export NN O
sales RB O
but IN O
we PRP$ O
must JJ O
have CC O
regard JJ O
to NN O
the VBZ O
terms NN O
and NNS O
objectives CC O
of PRP O
the MD O
policy VB O
and NN O
try TO O
to DT O
understand NNS O
that CC O
expression NNS O
accordingly IN O
para DT O
9 NN O
of CC O
the VB O
drug TO O
policy VB O
1994 DT O
makes NN O
it RB O
clear VBZ O
that CD O
the IN O
high DT O
turnover NN O
of NN O
a CD O
drug VBZ O
is PRP O
an JJ O
index IN O
of DT O
its JJ O
extent NN O
of IN O
usage DT O
usage NN O
has VBZ O
obvious DT O
reference NN O
to IN O
consumption PRP$ O
and NN O
consumption IN O
within JJ O
the NN O
domestic VBZ O
market JJ O
whether NN O
the TO O
drug NN O
is CC O
extensively NN O
used IN O
within DT O
the JJ O
country NN O
is IN O
one DT O
of NN O
the VBZ O
considerations RB O
kept VBN O
in IN O
view DT O
to NN O
clamp VBZ O
price CD O
control IN O
the DT O
export NNS O
potential VBD O
of IN O
the NN O
drug TO O
or VB O
its NN O
usage NN O
in DT O
foreign NN O
countries NN O
could IN O
not DT O
have NN O
been CC O
the PRP$ O
reason NN O
to IN O
notify JJ O
the NNS O
specified MD O
drugs RB O
for VB O
price VBN O
control DT O
if NN O
there TO O
is VB O
any DT O
doubt JJ O
in NNS O
this IN O
regard NN O
it NN O
is IN O
dispelled EX O
by VBZ O
what DT O
is NN O
stated IN O
in DT O
paragraph NN O
10 PRP O
of VBZ O
the VBN O
rejoinder IN O
affidavit WP O
which VBZ O
we VBN O
quoted IN O
supra NN O
to CD O
repeat IN O
it DT O
was NN O
stated NN O
therein WDT O
that PRP O
the VBD O
intent NN O
behind TO O
using VB O
the PRP O
word VBD O
turnover VBN O
has NN O
been IN O
to DT O
determine NN O
the IN O
extent VBG O
of DT O
usage NN O
of NN O
a VBZ O
bulk VBN O
drug TO O
in VB O
the DT O
country NN O
it IN O
is NN O
also IN O
pertinent DT O
to JJ O
note NN O
that IN O
the DT O
govt NN O
of PRP O
india VBZ O
has RB O
not JJ O
come TO O
forward VB O
with IN O
any DT O
explanation NN O
as IN O
to NN O
why VBZ O
export RB O
sales VBN O
also RB O
should IN O
be DT O
taken NN O
into IN O
account TO O
in WRB O
assessing NN O
the NNS O
turnover RB O
as MD O
per VB O
the VBN O
criteria IN O
laid NN O
down IN O
in VBG O
the DT O
drug NN O
policy IN O
for IN O
all DT O
these NN O
reasons VBD O
we RB O
are IN O
in DT O
agreement NN O
with NN O
the IN O
high PDT O
court DT O
that NNS O
the PRP O
export VBP O
sales IN O
ought NN O
to IN O
have DT O
been JJ O
excluded NN O
while IN O
calculating DT O
the NN O
turnover NNS O
how MD O
far TO O
the VB O
exclusion VBN O
of VBN O
export IN O
sales VBG O
would DT O
make NN O
any WRB O
difference RB O
is DT O
a NN O
different IN O
matter NN O
59 NNS O
another MD O
grey VB O
area DT O
which NN O
has VBZ O
surfaced DT O
in JJ O
the NN O
backdrop CD O
of DT O
the NN O
drug NN O
policy WDT O
1994 VBZ O
is VBN O
whether IN O
for DT O
the NN O
purpose IN O
of DT O
clause NN O
iii NN O
the CD O
expression VBZ O
formulators IN O
should IN O
be DT O
confined NN O
to IN O
single NN O
ingredient VBP O
formulators DT O
or NN O
it NNS O
should MD O
extend VB O
to VBN O
multi TO O
ingredient JJ O
formulators NN O
as NNS O
well CC O
the PRP O
nppa MD O
while VB O
rejecting TO O
the VB O
representation JJ O
of NNS O
the RB O
bulk RB O
drug DT O
manufacturers NN O
association IN O
referred VBG O
to DT O
the NN O
clarification IN O
issued DT O
by JJ O
the NN O
government NNS O
of NN O
india VBD O
in TO O
its DT O
communication NN O
dated VBN O
106197 IN O
addressed DT O
to NN O
one IN O
of NN O
the IN O
writ PRP$ O
petitioners NN O
which VBD O
is CD O
as VBD O
follows TO O
the CD O
basis IN O
of DT O
the NN O
single NNS O
ingredient WDT O
formulation VBZ O
as IN O
against VBZ O
that DT O
of NN O
the IN O
combination DT O
formulation JJ O
for NN O
purpose NN O
of IN O
calculating IN O
market IN O
share IN O
is DT O
not NN O
only NN O
justified IN O
on NN O
account IN O
of VBG O
predominance NN O
of NN O
single VBZ O
ingredient RB O
formulation RB O
on JJ O
over IN O
all NN O
basis IN O
but NN O
also IN O
vindicates JJ O
the NN O
objective NN O
of IN O
promoting IN O
the DT O
rational NN O
use CC O
of RB O
drugs VBZ O
in DT O
the NN O
country IN O
mentioned VBG O
in DT O
paragraph JJ O
1b NN O
of IN O
the NNS O
modifications IN O
in DT O
drug NN O
policy VBD O
1986 IN O
the NN O
principle CD O
of IN O
covering DT O
only NNS O
single IN O
ingredient NN O
formulations NN O
for CD O
purposes DT O
of NN O
calculating IN O
market VBG O
share RB O
is JJ O
a NN O
transparent NNS O
objective IN O
and NNS O
verifiable IN O
principle VBG O
and NN O
hence NN O
suitable VBZ O
for DT O
policy JJ O
issues NN O
formulations CC O
of JJ O
a NN O
bulk CC O
drug NN O
containing JJ O
one IN O
or NN O
more NNS O
other NNS O
bulk IN O
drug DT O
are JJ O
not NN O
comparable VBG O
in CD O
terms CC O
of JJR O
their JJ O
sales JJ O
values NN O
therefore VBP O
it RB O
is JJ O
practically IN O
not NNS O
possible IN O
to PRP$ O
apply NNS O
the NNS O
criteria IN O
relating PRP O
to VBZ O
market RB O
share RB O
of JJ O
a TO O
formulator VB O
of DT O
a NNS O
bulk VBG O
drug TO O
on NN O
the NN O
basis IN O
of DT O
data NN O
of IN O
its DT O
combination JJ O
formulations NN O
across IN O
the DT O
board NN O
in IN O
a NNS O
transparent IN O
objective PRP$ O
and NN O
verifiable NNS O
manner IN O
as DT O
required NN O
for IN O
policy DT O
issues JJ O
it NN O
is CC O
therefore JJ O
contended NN O
by IN O
the VBN O
union IN O
of NN O
india NNS O
that PRP O
only VBZ O
single RB O
ingredient VBN O
formulations IN O
have DT O
to NN O
be IN O
taken NN O
into IN O
account RB O
for JJ O
the NN O
purpose NNS O
of VBP O
working TO O
out VB O
the VBN O
criterion IN O
in NN O
clause IN O
iii DT O
and NN O
that IN O
the VBG O
number RP O
of DT O
single NN O
ingredient IN O
formulators NN O
of NN O
the CC O
concerned IN O
bulk DT O
drug NN O
is IN O
not JJ O
discernible NN O
from NNS O
org IN O
data DT O
of JJ O
course JJ O
it NN O
is VBZ O
the RB O
contention JJ O
of IN O
the JJ O
respondents NNS O
that IN O
no NN O
such PRP O
distinction VBZ O
can DT O
be NN O
drawn IN O
it DT O
is NNS O
contended WDT O
that DT O
such JJ O
distinction NN O
is MD O
irrational VB O
in VBN O
our PRP O
view VBZ O
the VBN O
clarification IN O
given JJ O
by NN O
the VBZ O
government JJ O
of IN O
india PRP$ O
reflects NN O
a DT O
reasonable NN O
view VBN O
point IN O
and DT O
it NN O
cannot IN O
be NN O
said VBZ O
that DT O
by JJ O
adopting NN O
such NN O
approach CC O
a PRP O
distorted MD O
meaning RB O
is VB O
given VBD O
to IN O
the IN O
expression VBG O
formulator JJ O
much NN O
against DT O
the JJ O
spirit NN O
of VBZ O
the VBN O
policy TO O
at DT O
any NN O
rate NN O
two RB O
views IN O
are DT O
possible NN O
and IN O
it DT O
is NN O
not IN O
for DT O
the NN O
court CD O
to NNS O
decide VBP O
which JJ O
view CC O
is PRP O
preferable VBZ O
6 RB O
before IN O
closing DT O
the NN O
discussion TO O
on VB O
the WDT O
controversies NN O
surrounding VBZ O
the JJ O
criteria CD O
evolved IN O
in VBG O
the DT O
drug NN O
policy IN O
there DT O
is NNS O
one VBG O
argument DT O
of NNS O
the VBN O
learned IN O
solicitor DT O
general NN O
which NN O
we EX O
would VBZ O
like CD O
to NN O
refer IN O
to DT O
the JJ O
learned NN O
solicitor JJ O
general WDT O
argued PRP O
that MD O
the VB O
expression TO O
may VB O
occurring TO O
in DT O
clause VBN O
iii NN O
of JJ O
para VBD O
2272 IN O
of DT O
the NN O
drug MD O
policy VB O
confers IN O
discretion NN O
and NN O
flexibility IN O
in NN O
approach CD O
to IN O
the DT O
government NN O
of NN O
india NNS O
even NN O
if CC O
a NN O
particular IN O
bulk NN O
drug TO O
stands DT O
outside NN O
price IN O
control NN O
by RB O
the IN O
application DT O
of JJ O
such NN O
criteria NN O
the NNS O
discretion JJ O
is NN O
still NN O
left IN O
to DT O
the NN O
government IN O
to JJ O
include NNS O
the DT O
drug NN O
in VBZ O
the RB O
schedule VBN O
for TO O
good DT O
reasons NN O
this TO O
argument VB O
cannot DT O
be NN O
countenanced IN O
for DT O
the NN O
simple IN O
reason JJ O
that NNS O
it DT O
is NN O
not MD O
the RB O
case VB O
of VBN O
the IN O
government DT O
that JJ O
for NN O
any IN O
particular PRP O
reason VBZ O
or RB O
reasons DT O
the NN O
bulk IN O
drug DT O
concerned NN O
was IN O
brought IN O
within DT O
the JJ O
purview NN O
of CC O
price NNS O
control DT O
though JJ O
the NN O
drug VBN O
qualifies VBD O
for VBN O
exclusion IN O
under DT O
clause NN O
iii IN O
even NN O
assuming NN O
that IN O
the DT O
discretion NN O
is NNS O
available IN O
in NN O
terms IN O
of NN O
the NN O
policy RB O
the VBG O
factum IN O
of DT O
exercising NN O
such VBZ O
discretion JJ O
for IN O
relevant NNS O
reasons IN O
should DT O
be NN O
disclosed DT O
in NN O
the IN O
absence VBG O
of JJ O
such NN O
disclosure IN O
the JJ O
court NNS O
must MD O
proceed VB O
on VBN O
the IN O
basis DT O
that NN O
the IN O
government JJ O
stood NN O
by DT O
the NN O
criteria MD O
and VB O
saw IN O
no DT O
need NN O
to IN O
deviate DT O
therefrom NN O
71 VBD O
now IN O
it DT O
is NNS O
necessary CC O
to VBD O
advert DT O
to NN O
the TO O
nature VB O
of IN O
the CD O
claim RB O
made PRP O
by VBZ O
the JJ O
writ TO O
petitioners VB O
in TO O
relation DT O
to NN O
each IN O
of DT O
the NN O
bulk VBN O
drugs IN O
the DT O
stand NN O
taken NNS O
by IN O
the NN O
union TO O
of DT O
india IN O
and DT O
the NN O
conclusions NNS O
of DT O
the NN O
high VBN O
court IN O
72 DT O
salbutamol NN O
according IN O
to NN O
the CC O
writ DT O
petitioner NNS O
company IN O
the DT O
annual JJ O
turnover NN O
for CD O
the NN O
year VBG O
ending TO O
march DT O
1990 NN O
was NN O
rs NN O
17117 DT O
lacs JJ O
based NN O
on IN O
the DT O
org NN O
data VBG O
the NN O
sales CD O
of VBD O
formulations JJ O
in CD O
domestic NN O
market VBN O
has IN O
been DT O
taken NN O
as VBD O
the DT O
basis NNS O
to IN O
calculate NNS O
the IN O
consumption JJ O
it NN O
is VBZ O
then VBN O
multiplied VBN O
by IN O
the DT O
notified NN O
price TO O
prevalent VB O
during DT O
the NN O
relevant PRP O
period VBZ O
it RB O
is VBN O
the IN O
further DT O
case JJ O
of NN O
the NN O
writ IN O
petitioner DT O
that JJ O
there NN O
was PRP O
as VBZ O
many DT O
as JJ O
24 NN O
formulations IN O
including DT O
the NN O
petitioner NN O
none IN O
of EX O
whom VBD O
had RB O
the JJ O
market IN O
share CD O
of NNS O
more VBG O
than DT O
40 NN O
admittedly NN O
there IN O
were WP O
more VBD O
than DT O
five NN O
bulk NN O
drug IN O
producers JJR O
the IN O
writ CD O
petitioner RB O
company EX O
therefore VBD O
claimed JJR O
the IN O
benefit CD O
of JJ O
exclusion NN O
both NNS O
under DT O
clause NN O
i NN O
and NN O
iii RB O
of VBD O
para DT O
2272 NN O
of IN O
the NN O
drug DT O
policy IN O
1994 NN O
the NN O
government CC O
of NN O
india IN O
took NN O
the CD O
stand IN O
that DT O
the NN O
bulk NN O
drug CD O
turnover DT O
was NN O
rs IN O
1150 NN O
crores VBD O
based DT O
on NN O
the IN O
value DT O
of JJ O
domestic NN O
production NN O
and VBD O
imports JJ O
moreover CD O
there NNS O
were VBN O
only IN O
seven DT O
known NN O
formulators IN O
of JJ O
the NN O
bulk CC O
drug NNS O
therefore RB O
it EX O
is VBD O
contended RB O
that CD O
the JJ O
drug NNS O
salbutamol IN O
does DT O
not JJ O
qualify NN O
for IN O
exclusion PRP O
either VBZ O
under VBN O
clause IN O
i DT O
or NN O
iii NN O
the VBZ O
high RB O
court VB O
accepted IN O
the NN O
claim CC O
of IN O
the NN O
petitioner NN O
company CC O
on VB O
the DT O
ground JJ O
that NN O
in VBD O
the DT O
counter NN O
affidavit IN O
filed DT O
by NN O
the NN O
union IN O
of DT O
india NN O
there IN O
was IN O
only DT O
a NN O
bald NN O
denial VBN O
and IN O
the DT O
details NN O
given IN O
by NN O
the EX O
writ VBD O
petitioners RB O
were DT O
not JJ O
controverted NN O
73 CC O
theophylline DT O
the NNS O
writ VBN O
petitioners IN O
claimed DT O
exclusion NN O
under NNS O
clause VBD O
iii RB O
the VBN O
names CD O
of IN O
six DT O
bulk NN O
drug NNS O
producers VBD O
and NN O
31 IN O
formulators NN O
were VBP O
given DT O
in NNS O
the IN O
writ CD O
petition JJ O
in NN O
the NNS O
counter CC O
affidavit CD O
it NNS O
was VBD O
merely VBN O
stated IN O
that DT O
there NN O
were NN O
less IN O
than DT O
five NN O
known NN O
manufacturers PRP O
of VBD O
bulk RB O
drug VBN O
and IN O
less EX O
than VBD O
10 JJR O
known IN O
formulators CD O
of JJ O
the NNS O
bulk IN O
drug JJ O
and NN O
therefore CC O
the JJR O
drug IN O
theophylline CD O
did JJ O
not NNS O
qualify IN O
for DT O
exclusion JJ O
under NN O
clause CC O
iii RB O
the DT O
high NN O
court NN O
observed VBD O
that RB O
the VB O
particulars IN O
furnished NN O
by IN O
the NN O
petitioner VBP O
were DT O
not JJ O
effectively NN O
controverted VBD O
there IN O
being DT O
only NNS O
a VBN O
bald IN O
denial DT O
it NN O
was VBD O
therefore RB O
held RB O
that VBN O
the EX O
drug VBG O
ought RB O
not DT O
to JJ O
have NN O
been PRP O
brought VBD O
under RB O
price VBN O
control IN O
as DT O
per NN O
the MD O
statement RB O
furnished TO O
by VB O
the VBN O
learned VBN O
solicitor IN O
general NN O
at NN O
the IN O
time IN O
of DT O
hearing NN O
the VBN O
fact IN O
that DT O
there JJ O
were NN O
more NN O
than IN O
five DT O
bulk NN O
drug IN O
producers VBG O
was DT O
accepted NN O
but IN O
the EX O
number VBD O
of JJR O
formulators IN O
was CD O
given JJ O
as NN O
seven NNS O
therefore VBD O
the VBN O
dispute CC O
is DT O
confined NN O
to IN O
the NNS O
number VBD O
of VBN O
formulators IN O
the CD O
term IN O
formulator DT O
being NN O
understood VBZ O
in VBN O
the TO O
sense DT O
in NN O
which IN O
the NNS O
government DT O
of NN O
india NN O
explained VBG O
in VBN O
its IN O
clarificatory DT O
letter NN O
dated IN O
6 WDT O
4 DT O
1998 NN O
74 IN O
cloxacillin NN O
the VBN O
writ IN O
petitioners PRP$ O
concerned NN O
are NN O
said VBD O
to CD O
be CD O
the CD O
manufacturers CD O
of NN O
formulations DT O
made NN O
out NNS O
of VBN O
cloxacillin VBP O
there VBD O
is TO O
no VB O
dispute DT O
that NNS O
the IN O
annual NNS O
turnover VBN O
at IN O
the IN O
relevant NN O
time EX O
was VBZ O
much DT O
more NN O
than IN O
400 DT O
lacs JJ O
the NN O
writ IN O
petitioners DT O
claimed JJ O
exclusion NN O
of VBD O
the RB O
drug JJR O
cloxacillin IN O
on CD O
the CC O
basis DT O
of NN O
clause NNS O
iii VBD O
of NN O
para IN O
2272 DT O
according NN O
to NN O
them IN O
there DT O
were NN O
as IN O
many NN O
as NN O
16 IN O
bulk NN O
drug CD O
procedures VBG O
and TO O
23 PRP O
formulators EX O
in VBD O
respect RB O
of JJ O
cloxacillin IN O
and CD O
none JJ O
of NN O
the NNS O
formulators CC O
had CD O
more NNS O
than IN O
40 NN O
market IN O
share NN O
as CC O
per NN O
the IN O
org DT O
figures NNS O
for VBD O
the JJR O
year IN O
1989 CD O
90 NN O
upto NN O
march IN O
1990 IN O
the DT O
high NN O
court NNS O
accepted IN O
the DT O
case NN O
of CD O
the CD O
petitioners IN O
on NN O
the CD O
ground DT O
that JJ O
the NN O
factual VBD O
particulars DT O
were NN O
not IN O
controverted DT O
but NNS O
there IN O
was DT O
only NN O
a IN O
bald DT O
denial JJ O
in NNS O
the VBD O
counter RB O
affidavit VBN O
filed CC O
by EX O
union VBD O
of RB O
india DT O
the JJ O
counter NN O
affidavit IN O
of DT O
union NN O
of NN O
india VBN O
is IN O
not NN O
found IN O
either VBG O
in DT O
slp NN O
paper NN O
books IN O
or NN O
the IN O
original NN O
record VBZ O
of RB O
high VBN O
court RB O
however IN O
the JJ O
stand NN O
of NNS O
union CC O
of DT O
india JJ O
as NN O
is IN O
clear JJ O
from NN O
the RB O
reply DT O
dated NN O
641998 IN O
of NN O
the IN O
nppa NN O
sent IN O
to VBZ O
the JJ O
bulk IN O
drug DT O
manufacturers NN O
association VBD O
as CD O
well IN O
as DT O
the JJ O
grounds NN O
of TO O
slp DT O
is JJ O
that NN O
the NNS O
number NN O
of RB O
single RB O
ingredient IN O
formulators DT O
of NNS O
the IN O
drug NN O
was VBZ O
less IN O
than DT O
10 NN O
according IN O
to JJ O
the NN O
statement NNS O
furnished IN O
by DT O
the NN O
learned VBD O
solicitor JJR O
general IN O
in CD O
the VBG O
course TO O
of DT O
the NN O
arguments VBN O
the IN O
number DT O
of JJ O
formulators NN O
were NN O
only IN O
two DT O
the NN O
nppa IN O
clarified DT O
the NNS O
position DT O
thus NN O
the IN O
association NNS O
has VBD O
claimed RB O
that CD O
the DT O
highest NN O
market VBD O
share DT O
of NN O
single RB O
formulator DT O
is NN O
2189 VBZ O
this VBN O
claim IN O
is DT O
based JJS O
on NN O
consideration NN O
of IN O
sale JJ O
values NN O
of VBZ O
both CD O
single DT O
ingredient NN O
and VBZ O
combination VBN O
products IN O
of NN O
cloxacillin IN O
however NN O
the NNS O
highest IN O
market DT O
share JJ O
of NN O
single CC O
drug NN O
ingredient NNS O
formulation IN O
of NN O
a RB O
particular DT O
formulator JJS O
works NN O
out NN O
to IN O
9307 JJ O
which NN O
is NN O
more NN O
than IN O
the DT O
stipulated JJ O
level NN O
of VBZ O
40 RP O
thus TO O
there CD O
is WDT O
controversy VBZ O
regarding JJR O
the IN O
number DT O
of JJ O
formulators NN O
and IN O
their CD O
market RB O
share EX O
75 VBZ O
cyproflaxacin NN O
the VBG O
2nd DT O
petitioner NN O
in IN O
writ NNS O
petition CC O
no PRP$ O
3449 NN O
of NN O
1996 CD O
namely VBD O
ranbaxy DT O
laboratories CD O
ltd NN O
produced IN O
the JJ O
said NN O
bulk DT O
drug CD O
during IN O
the CD O
relevant RB O
period JJ O
and NNS O
captivity VBP O
consumed VBD O
the DT O
same VBD O
in JJ O
the NN O
manufacture IN O
of DT O
formulations JJ O
marketed NN O
under CC O
the NN O
brand VBD O
name DT O
of JJ O
cifran IN O
both DT O
in NN O
india IN O
and NNS O
foreign VBN O
countries IN O
the DT O
petitioner NN O
in NN O
wpno IN O
1974 NN O
of DT O
2000 IN O
is NN O
cipla CC O
ltd JJ O
inter NNS O
alia DT O
it NN O
is IN O
engaged JJ O
in CD O
the IN O
manufacture CD O
and VBZ O
sale VBN O
of JJ O
formulations NN O
of IN O
the PRP O
drug VBZ O
cyproflaxacin VBN O
according IN O
to DT O
ranbaxy NN O
ltd CC O
the NN O
annual IN O
domestic NNS O
turnover IN O
of DT O
the NN O
drug NN O
for VBG O
the TO O
year VB O
ending PDT O
march DT O
1990 JJ O
was JJ O
rs NN O
238 IN O
lacs DT O
and NN O
according IN O
to DT O
the NN O
cipla VBG O
ltd NN O
it CD O
was VBD O
rs JJ O
243 CD O
lacs NN O
excluding CC O
the VBG O
hospital TO O
and DT O
institutional NN O
sales VBD O
to PRP O
the VBD O
extent JJ O
of CD O
15 NN O
it VBG O
is DT O
therefore NN O
contended CC O
that JJ O
the NNS O
drug TO O
stands DT O
excluded NN O
under IN O
clause CD O
i PRP O
of VBZ O
para RB O
2272 VBN O
of IN O
the DT O
drugs NN O
policy VBZ O
it VBN O
is IN O
their NN O
further NN O
contention IN O
that NN O
there CD O
was IN O
no DT O
monopoly NNS O
situation NN O
as PRP O
contemplated VBZ O
by PRP$ O
clause JJ O
ii NN O
inasmuch IN O
as EX O
there VBD O
was DT O
no JJ O
single NN O
formulator IN O
having VBN O
90 IN O
or NN O
more NN O
market JJ O
share IN O
in EX O
the VBD O
retail DT O
trade JJ O
as NN O
per VBG O
org CD O
data CC O
the JJR O
said NN O
turnover NN O
was IN O
calculated DT O
on JJ O
the NN O
basis IN O
of IN O
estimated NN O
consumption NNS O
purportedly DT O
arrived VBD O
at NN O
with VBD O
reference VBN O
to IN O
the DT O
data NN O
relating IN O
to VBN O
sales NN O
formulations RB O
given VBD O
in IN O
org IN O
publication NN O
the TO O
quantum DT O
of NNS O
consumption VBG O
was TO O
then NNS O
multiplied NNS O
by VBN O
the IN O
then JJ O
prevailing NN O
market DT O
price NN O
however IN O
a NN O
different VBD O
method RB O
of VBN O
calculation IN O
of DT O
turnover RB O
was VBG O
spelt NN O
out NN O
in RB O
the DT O
representation JJ O
dated NN O
731995 IN O
submitted NN O
by IN O
ranbaxy NN O
ltd VBD O
to VBN O
government RP O
of IN O
india DT O
vide NN O
extb VBD O
in CD O
wpno VBN O
3449 IN O
of NN O
1996 NN O
according TO O
to NN O
that IN O
calculation JJ O
the NN O
turnover NN O
is IN O
rs JJ O
280 CD O
lacs IN O
in CD O
the VBG O
counter TO O
affidavit DT O
the NN O
turnover DT O
given NN O
by VBZ O
the JJ O
writ CD O
petitioners NN O
has IN O
been DT O
disputed NN O
it IN O
is DT O
stated NN O
that VBN O
org IN O
data DT O
relates NN O
to NNS O
formulation VBZ O
sales VBN O
and VBN O
it PRP O
does VBZ O
not VBN O
give IN O
data NN O
in NNS O
regard VBZ O
to TO O
quantities VB O
and NNS O
values CC O
of PRP O
bulk VBZ O
drugs RB O
involved VB O
it NNS O
was IN O
also NN O
stated TO O
that NNS O
cyproflaxacin CC O
was NNS O
included IN O
in NN O
the NNS O
first VBD O
schedule PRP O
on VBD O
the RB O
basis VBN O
of IN O
criterion NN O
in VBD O
clause VBN O
i IN O
since DT O
the JJ O
turnover NN O
in IN O
1989 DT O
90 NN O
was IN O
taken NN O
as IN O
rs NN O
990 NN O
lacs IN O
based DT O
on NN O
the IN O
landed CD O
cost CD O
of VBD O
imports VBN O
of IN O
the JJ O
drug CD O
it NN O
is VBN O
then IN O
stated DT O
that JJ O
the NN O
data IN O
in NNS O
regard IN O
to DT O
indigenous NN O
production PRP O
is VBZ O
not RB O
available VBN O
the IN O
high DT O
court NNS O
merely IN O
referred NN O
to TO O
the JJ O
contention NN O
of VBZ O
the RB O
writ JJ O
petitioners DT O
regarding JJ O
the NN O
turnover RB O
and VBD O
accepted TO O
the DT O
same NN O
on IN O
the DT O
ground NN O
that NNS O
there VBG O
was DT O
only NN O
bald CC O
denial VBD O
in DT O
the JJ O
affidavit IN O
in DT O
reply NN O
surprisingly IN O
the EX O
high VBD O
court RB O
extended JJ O
the NN O
benefit IN O
of DT O
exclusion NN O
under IN O
clause NN O
iii RB O
also DT O
though JJ O
it NN O
was VBD O
never DT O
the NN O
case IN O
of NN O
the IN O
writ NN O
petitioners NN O
the RB O
high IN O
court PRP O
stated VBD O
that RB O
there DT O
were NN O
admittedly IN O
16 DT O
bulk NN O
drug VBZ O
procedures DT O
and JJ O
20 NN O
formulators VBD O
though IN O
no EX O
such VBD O
case RB O
was CD O
set JJ O
up NN O
by NNS O
either CC O
of CD O
the NNS O
writ IN O
petitioners DT O
in JJ O
the NN O
org VBD O
data VBN O
furnished RP O
by IN O
the DT O
petitioner IN O
in DT O
wpno NN O
3449 NNS O
of IN O
1996 DT O
and NN O
in NNS O
the VBN O
representation IN O
submitted DT O
to NN O
the IN O
government JJ O
of CD O
india IN O
only CD O
the CC O
names IN O
of DT O
seven NN O
formulators VBN O
was TO O
mentioned DT O
thus NN O
there IN O
was NN O
an RB O
obvious DT O
error NNS O
in IN O
the CD O
high NNS O
court VBD O
s VBN O
judgment RB O
the EX O
plea VBD O
of DT O
discrimination JJ O
which NN O
was IN O
raised DT O
for JJ O
the NN O
first VBD O
time NN O
in DT O
the NN O
rejoinder IN O
affidavit NN O
filed WDT O
in VBD O
wpno VBN O
3349 IN O
of DT O
1996 JJ O
also NN O
found IN O
favour DT O
with NN O
the NN O
high VBN O
court IN O
76 NN O
norfloxacin CD O
the IN O
writ CD O
petitioner RB O
seeks VBD O
exclusion RB O
from IN O
the DT O
purview JJ O
of NN O
dpco CD O
on IN O
the DT O
basis NN O
of NN O
clause VBZ O
iii NN O
of IN O
para DT O
2272 NN O
of IN O
the NN O
drugs IN O
policy DT O
it NN O
is IN O
the NN O
case NN O
of IN O
the NN O
petitioner CD O
that IN O
there DT O
were NNS O
at NN O
least PRP O
28 VBZ O
bulk DT O
drug NN O
manufacturers IN O
and DT O
20 NN O
formulators IN O
and EX O
no VBD O
single IN O
formulator JJS O
had CD O
more JJ O
than NN O
40 NNS O
market CC O
share CD O
as NNS O
per CC O
the DT O
org JJ O
figures NN O
the VBD O
names JJR O
were IN O
given CD O
in NN O
the NN O
writ IN O
petition IN O
however DT O
the NN O
stand VBZ O
taken DT O
in NNS O
the VBD O
counter VBN O
affidavit IN O
filed DT O
by NN O
the NN O
government RB O
of DT O
india NN O
is VBN O
that IN O
there DT O
were NN O
only NN O
three VBN O
manufacturers IN O
of DT O
the NN O
bulk IN O
drug NN O
and VBZ O
the IN O
org EX O
data VBD O
does RB O
not CD O
disclose NNS O
the IN O
number DT O
of JJ O
bulk NN O
drug CC O
producers DT O
as JJ O
regards NN O
the VBZ O
formulators RB O
the VB O
stand DT O
taken NN O
is IN O
that JJ O
the NN O
number NNS O
of IN O
single NNS O
ingredient DT O
formulators NNS O
using DT O
the NN O
said VBN O
bulk VBZ O
drug IN O
is DT O
not NN O
discernible IN O
from JJ O
the NN O
org NNS O
data VBG O
it DT O
is VBD O
therefore JJ O
contended NN O
that VBZ O
the RB O
twin JJ O
conditions IN O
of DT O
a NN O
minimum NNS O
of PRP O
five VBZ O
bulk RB O
drug VBN O
producers IN O
and DT O
at JJ O
least NNS O
10 IN O
formulators DT O
are NN O
not IN O
satisfied CD O
the JJ O
high NN O
court NNS O
accepted CC O
the IN O
plea JJS O
of CD O
the NNS O
writ VBP O
petition RB O
on VBN O
the DT O
ground JJ O
that NN O
there VBD O
was DT O
only NN O
a IN O
bald DT O
denial NN O
in NN O
the IN O
counter DT O
affidavit NN O
and IN O
no EX O
specific VBD O
particulars RB O
were DT O
given JJ O
to NN O
controvert IN O
the DT O
contention NN O
of NN O
the CC O
petitioner DT O
in JJ O
the NNS O
order VBD O
passed VBN O
by TO O
nppa VB O
in DT O
response NN O
to IN O
the DT O
representation NN O
of IN O
bulk DT O
drug NN O
manufacturers VBN O
association IN O
it NNS O
is IN O
stated NN O
that TO O
as DT O
per NN O
the IN O
records JJ O
available NN O
there NNS O
were VBP O
only PRP O
three VBZ O
bulk VBN O
drug IN O
manufacturers IN O
in IN O
the DT O
country NNS O
during JJ O
1989 EX O
90 VBD O
however RB O
the CD O
names JJ O
were NN O
not NNS O
furnished IN O
either DT O
in NN O
this IN O
document CD O
or CD O
the RB O
counter DT O
affidavit NNS O
as VBD O
per RB O
the VBN O
org RB O
data IN O
the DT O
market NN O
share CC O
of DT O
the NN O
formulation NN O
sold IN O
by IN O
the DT O
petitioner NN O
company VBZ O
was DT O
3956 NN O
vide NN O
annexure IN O
at DT O
page NN O
38 VBN O
of IN O
the DT O
original NN O
writ NN O
petition VBD O
record CD O
which JJ O
as NN O
pointed IN O
out NN O
by CD O
nppa IN O
is DT O
technically JJ O
lower NN O
than NN O
40 NN O
we WDT O
may RB O
add VBD O
that RP O
it IN O
is NN O
perilously VBZ O
close RB O
to JJR O
40 IN O
it CD O
should PRP O
also MD O
be VB O
noted IN O
that PRP O
the VBZ O
writ RB O
petitioner JJ O
did TO O
not CD O
furnish PRP O
any MD O
details RB O
of VB O
production VBN O
to IN O
show DT O
that NN O
the NN O
bulk VBD O
drug RB O
manufacturers VB O
mentioned DT O
by NNS O
it IN O
or NN O
at TO O
least VB O
five IN O
amongst DT O
them JJ O
actually NN O
produced NNS O
the VBN O
bulk IN O
drug PRP O
77 CC O
doxycycline IN O
it JJS O
is CD O
the NNS O
case PRP O
of RB O
the VBD O
writ DT O
petitioner JJ O
that NN O
it CD O
manufacture NN O
and PRP O
sells VBZ O
single DT O
ingredient NN O
formulation IN O
containing DT O
the NN O
bulk NN O
drug IN O
doxycycline PRP O
in NN O
a CC O
concentration VBZ O
of JJ O
100 NN O
mg NN O
per VBG O
capsule DT O
under JJ O
the NN O
brand NN O
name IN O
of DT O
doxy NN O
1 IN O
the CD O
annual NNS O
turnover IN O
of NN O
the IN O
bulk DT O
drug NN O
doxycycline NN O
according IN O
to JJ O
the CD O
writ DT O
petitioner JJ O
was NN O
rs IN O
316 DT O
lacs JJ O
it NN O
is NN O
seen VBG O
from TO O
the DT O
tabular NN O
statement NN O
appended VBD O
to JJ O
annexure CD O
a NN O
to PRP O
the VBZ O
writ VBN O
petition IN O
at DT O
pages JJ O
85 NN O
86 VBD O
of TO O
the VB O
original DT O
record TO O
the DT O
petitioner NN O
arrived NN O
at IN O
the NNS O
total CD O
domestic CD O
consumption IN O
of DT O
the JJ O
bulk NN O
drug DT O
with NN O
reference VBD O
to IN O
the DT O
org JJ O
data JJ O
pertaining NN O
to IN O
sales DT O
of JJ O
formulations NN O
in IN O
the NN O
market TO O
it DT O
is NN O
the NNS O
further VBG O
case TO O
of NNS O
the IN O
writ NNS O
petitioner IN O
that DT O
as NN O
per PRP O
org VBZ O
data DT O
there JJ O
were NN O
at IN O
least DT O
19 NN O
formulators NN O
producing IN O
doxycycline IN O
based IN O
formulations NN O
and NNS O
none EX O
of VBD O
them IN O
had JJS O
more CD O
than NNS O
40 VBG O
of NN O
market VBN O
share NNS O
in CC O
retail NN O
trade IN O
therefore PRP O
the VBD O
petitioner JJR O
claimed IN O
that CD O
the IN O
bulk NN O
drug NN O
doxycycline IN O
should JJ O
have NN O
been IN O
excluded DT O
from NN O
the VBD O
purview IN O
of DT O
price JJ O
control NN O
in NN O
terms MD O
of VB O
under VBN O
clause VBN O
i IN O
iii DT O
and NN O
that IN O
monopoly NN O
situation NN O
contemplated IN O
by NNS O
clause IN O
ii IN O
has NN O
no NN O
application NN O
because CC O
no IN O
single JJ O
manufacturer NN O
had VBN O
90 IN O
or NN O
more NN O
market VBZ O
share DT O
in NN O
retail IN O
trade DT O
the JJ O
stand NN O
of VBD O
the CD O
government CC O
has JJR O
been NN O
that NN O
the IN O
turnover JJ O
of NN O
doxycycline DT O
was NN O
above IN O
400 DT O
lacs NN O
during VBZ O
the VBN O
relevant IN O
period DT O
and NN O
therefore IN O
it NN O
comes VBD O
under IN O
price CD O
control NN O
further IN O
it DT O
is JJ O
their NN O
case CC O
that VB O
clause PRP O
ii VBZ O
has IN O
no NN O
application NN O
because RBR O
the PRP O
turnover VBZ O
is PRP$ O
above NN O
400 IN O
lacs NN O
it NN O
is VBZ O
also DT O
averred NN O
in IN O
the DT O
counter NN O
affidavit VBZ O
that IN O
the CD O
retail NN O
trade PRP O
sale VBZ O
data RB O
is VBN O
not IN O
relevant DT O
since NN O
the NN O
need IN O
to DT O
calculate JJ O
market NN O
share NN O
does NNS O
not VBZ O
arise RB O
moreover JJ O
since IN O
undisputably DT O
there NN O
is TO O
only VB O
one NN O
manufacturer NN O
of VBZ O
the RB O
bulk VB O
drug RB O
ie IN O
ranbaxy RB O
limited EX O
the VBZ O
exclusion RB O
criteria CD O
laid NN O
down IN O
in DT O
clause JJ O
iii NN O
of NN O
para NN O
2272 VBD O
is DT O
not NN O
applicable NN O
in VBD O
paragraph RB O
89 IN O
of NN O
the NN O
judgment IN O
under NN O
appeal CD O
the VBZ O
high RB O
court JJ O
having IN O
merely JJ O
referred CD O
to IN O
the DT O
arguments NN O
of IN O
the NN O
learned DT O
counsel JJ O
for NN O
the VBG O
petitioner RB O
accepted VBN O
the TO O
case DT O
of NNS O
the IN O
petitioner DT O
on JJ O
the NN O
ground IN O
that DT O
in NN O
the VBD O
affidavit DT O
in NN O
reply IN O
filed DT O
by NN O
the IN O
government DT O
there NN O
was IN O
only IN O
bald DT O
denial NN O
and IN O
that NN O
the VBN O
particulars IN O
were DT O
not NN O
controverted EX O
moreover VBD O
the RB O
high JJ O
court NN O
was CC O
under IN O
an DT O
apparent NNS O
misapprehension VBD O
that RB O
the VBN O
writ IN O
petitioner DT O
sought JJ O
the NN O
benefit VBD O
of IN O
exclusion DT O
under JJ O
clause NN O
iii IN O
also DT O
the NN O
core NN O
controversy VBD O
as DT O
already NN O
noticed IN O
is NN O
regarding IN O
the NN O
quantum NN O
of RB O
turnover DT O
the NN O
union NN O
of IN O
india RB O
took VBN O
the VBZ O
stand VBG O
that DT O
the NN O
turnover IN O
was NN O
above DT O
400 NN O
lacs IN O
in NN O
the VBD O
statement DT O
filed NN O
by IN O
the DT O
learned NN O
solicitor VBD O
general IN O
at CD O
the NN O
time IN O
of DT O
argument NN O
the VBN O
figure IN O
was DT O
given JJ O
as NN O
47177 NN O
lacs IN O
however DT O
the NN O
appellant IN O
did NN O
not DT O
furnish NN O
any VBD O
details VBN O
as IN O
to CD O
the NN O
calculation RB O
of DT O
turnover NN O
78 VBD O
glipizide RB O
the VB O
writ DT O
petitioner NNS O
usv IN O
limited TO O
is DT O
a NN O
manufacture IN O
of NN O
the CD O
bulk IN O
drug DT O
glipizide NN O
which NN O
is JJ O
sold VBN O
under VBZ O
the DT O
brand NN O
name IN O
of DT O
glynase JJ O
it NN O
does NN O
not WDT O
appear VBZ O
that VBN O
there IN O
was DT O
any NN O
other NN O
producer IN O
of NN O
bulk PRP O
drug VBZ O
during RB O
the VB O
relevant IN O
period EX O
it VBD O
is DT O
the JJ O
case NN O
of IN O
the JJ O
writ NN O
petitioner IN O
that DT O
the JJ O
annual NN O
turnover PRP O
for VBZ O
the DT O
year NN O
ending IN O
31st DT O
march NN O
1990 NN O
was IN O
only DT O
rs JJ O
82 NN O
lacs IN O
and DT O
that NN O
clause VBG O
ii CD O
is NN O
not CD O
therefore VBD O
attracted RB O
the JJ O
writ CD O
petitioner NN O
estimated CC O
the IN O
turnover NN O
figure NN O
by VBZ O
arriving RB O
at RB O
the VBD O
consumption DT O
of NN O
the NN O
bulk VBD O
drug DT O
in NN O
various NN O
formulations IN O
and VBG O
by IN O
multiplying DT O
the NN O
same IN O
by DT O
the JJ O
mrp NN O
maximum IN O
retail JJ O
price NNS O
the CC O
org IN O
data VBG O
relating DT O
to JJ O
sales IN O
of DT O
formulations NN O
was JJ O
furnished JJ O
the NN O
stand DT O
of NN O
the NNS O
central VBG O
government TO O
is NNS O
that IN O
production NNS O
data VBD O
was VBN O
not DT O
available NN O
for IN O
the DT O
year JJ O
1989 NN O
90 VBZ O
and IN O
the NN O
turnover NNS O
of VBD O
the RB O
bulk JJ O
drug IN O
was DT O
determined NN O
by CD O
the CD O
expert CC O
group DT O
on NN O
the IN O
basis DT O
of JJ O
the NN O
landed VBD O
cost VBN O
of IN O
imports DT O
during NN O
the NN O
year IN O
to DT O
the NN O
tune IN O
of DT O
rs JJ O
32250 NN O
lacs IN O
as NNS O
there IN O
was DT O
only NN O
one TO O
formulator DT O
as NN O
reported IN O
in NN O
org CD O
survey NN O
of IN O
march EX O
1990 VBD O
monopoly RB O
situation CD O
was NN O
considered IN O
to VBN O
be IN O
existing JJ O
since NN O
one IN O
formulator NN O
was CD O
having NN O
100 NN O
market VBD O
share VBN O
as TO O
on VB O
3131990 VBG O
disputing IN O
the CD O
assertion NN O
of VBD O
the VBG O
writ CD O
petitioner NN O
that NN O
as IN O
per IN O
org CD O
data VBG O
furnished DT O
in NN O
extf IN O
to DT O
the NN O
writ NN O
petition IN O
there IN O
was IN O
no NN O
single NNS O
formulator VBN O
having IN O
90 NN O
or TO O
more DT O
market NN O
share NN O
in EX O
retail VBD O
trade DT O
it JJ O
is NN O
pointed VBG O
out CD O
in CC O
paragraph JJR O
iv NN O
of NN O
the IN O
counter JJ O
affidavit NN O
that PRP O
extf VBZ O
includes VBN O
formulations RP O
based IN O
on NN O
the NN O
bulk IN O
drugs DT O
other NN O
than NN O
glipizide WDT O
it VBZ O
is VBZ O
further NNS O
stated VBN O
in IN O
the DT O
same NN O
para NNS O
of JJ O
the IN O
counter VB O
that PRP O
there VBZ O
is JJ O
only VBN O
one IN O
formulation DT O
namely JJ O
glynase NN O
based IN O
on DT O
glipizide NN O
and IN O
in EX O
respect VBZ O
of RB O
that CD O
the NN O
writ RB O
petitioner NN O
had VBN O
100 IN O
market NN O
share CC O
thus IN O
the NN O
dispute IN O
mainly IN O
centers DT O
round NN O
the NN O
quantum VBD O
of CD O
turnover NN O
the NN O
high RB O
court DT O
observed NN O
that RB O
even NNS O
assuming VBP O
that DT O
the NN O
petitioners IN O
were NN O
the DT O
sole JJ O
manufacturers NN O
of VBD O
the IN O
said RB O
drug VBG O
as IN O
the DT O
turnover NNS O
was VBD O
below DT O
rs JJ O
100 NNS O
lacs IN O
the DT O
monopoly VBD O
situation NN O
as IN O
envisaged DT O
in NN O
para VBD O
2272 IN O
ii JJ O
of CD O
drug IN O
policy DT O
1994 NN O
does NN O
not IN O
apply VBN O
and IN O
as NN O
such CD O
the NN O
said IN O
drug NN O
ought NN O
to CD O
be VBZ O
kept RB O
out VB O
of CC O
the IN O
purview JJ O
of DT O
dpco VBD O
1995 NN O
the MD O
plea TO O
of VB O
discrimination VBN O
between IN O
this IN O
drug DT O
and NN O
another IN O
anti NN O
diabetic CD O
drug DT O
known NN O
as IN O
insulin NN O
also IN O
found DT O
favour NN O
with CC O
the DT O
high JJ O
court JJ O
81 NN O
we VBN O
are IN O
of NN O
the RB O
view VBD O
that RB O
the IN O
approach DT O
of JJ O
high NN O
court CD O
in PRP O
considering VBP O
the IN O
question DT O
of NN O
applicability IN O
of DT O
criteria NN O
laid IN O
down JJ O
in NN O
the IN O
drugs VBG O
policy DT O
in NN O
relation IN O
to NN O
each IN O
of NNS O
the VBN O
above RB O
drugs IN O
is DT O
not NNS O
correct NN O
and IN O
the NN O
high TO O
court DT O
failed IN O
to DT O
address JJ O
itself NNS O
to VBZ O
various RB O
crucial JJ O
aspects CC O
as DT O
indicated JJ O
below NN O
82 VBD O
org TO O
data VB O
does PRP O
not TO O
give JJ O
full JJ O
and NNS O
clear IN O
picture VBN O
of IN O
the CD O
turnover NNS O
of NN O
bulk VBZ O
drug RB O
org VB O
data JJ O
relates CC O
to JJ O
sales NN O
of IN O
formulations DT O
made NN O
either IN O
exclusively JJ O
out NN O
of NN O
the NNS O
bulk NNS O
drug TO O
or NNS O
in IN O
combination NNS O
with VBN O
other RB O
drugs RB O
the IN O
formulations IN O
containing DT O
the JJ O
particular NN O
bulk CC O
drug IN O
either NN O
wholly IN O
or JJ O
in NNS O
part DT O
reach NNS O
the VBG O
consumers DT O
through JJ O
normal NN O
trade NN O
channels CC O
the RB O
particulars CC O
of IN O
sales NN O
of VBP O
such DT O
formulations NNS O
entering IN O
the JJ O
retail NN O
market NNS O
are DT O
compiled NNS O
by IN O
org NNS O
bulk IN O
drug JJ O
sales NNS O
as VBG O
such DT O
are JJ O
not NN O
covered VBP O
by VBN O
org IN O
data JJ O
at JJ O
best NN O
from NNS O
org IN O
data JJ O
it VBP O
may RB O
be VBN O
possible IN O
to JJ O
deduce NNS O
the IN O
consumption JJS O
of IN O
bulk NN O
drug NNS O
on PRP O
estimated MD O
basis VB O
especially JJ O
if TO O
it VB O
is DT O
the NN O
only IN O
drug JJ O
used NN O
in IN O
that VBN O
formulation NN O
moreover RB O
direct IN O
sales PRP O
to VBZ O
institutions DT O
such JJ O
as NN O
hospitals VBN O
and IN O
government DT O
organizations NN O
are RB O
not JJ O
reflected NNS O
in TO O
org NNS O
compilation JJ O
according IN O
to NNS O
the CC O
certificate NN O
filed NNS O
in VBP O
some RB O
of VBN O
the IN O
cases JJ O
such NN O
sales VBG O
would TO O
be DT O
about NN O
14 VBN O
it IN O
is DT O
also IN O
borne DT O
out NNS O
by JJ O
the NNS O
same MD O
certificate VB O
issued IN O
by CD O
the PRP O
associate VBZ O
research RB O
director VBN O
of RP O
org IN O
ext DT O
c JJ O
to NN O
wpno VBN O
1974 IN O
of DT O
2000 JJ O
and NN O
annexure NN O
i IN O
to JJ O
written JJ O
submissions NN O
that TO O
out VB O
of CD O
this IN O
86 CD O
the CC O
org NN O
data NN O
covers TO O
about VBN O
90 NNS O
of IN O
the IN O
retail IN O
market DT O
sales CD O
this DT O
is NN O
what NNS O
the NNS O
certificate IN O
says CD O
the IN O
retail DT O
pharma JJ O
market NN O
in NNS O
india DT O
contributes VBZ O
to WP O
86 DT O
of NN O
the VBZ O
total DT O
market JJ O
and NN O
the NN O
remaining IN O
14 JJ O
towards NNS O
hospital TO O
and CD O
institutional IN O
sales DT O
i JJ O
would NN O
like CC O
to DT O
confirm VBG O
that CD O
out NNS O
of NN O
this CC O
86 JJ O
of NNS O
retail RB O
pharma MD O
market VB O
org TO O
marg VB O
covers DT O
around IN O
90 IN O
through DT O
the CD O
retail IN O
store JJ O
audit NN O
rsa NN O
83 JJ O
one NN O
more VBZ O
aspect IN O
which CD O
deserves IN O
notice DT O
is JJ O
that NN O
from NN O
the VBD O
org CD O
data CD O
it JJR O
may NN O
not WDT O
be VBZ O
possible NN O
to VBZ O
ascertain IN O
whether IN O
the DT O
formulation NN O
is NNS O
made PRP O
up MD O
of RB O
single VB O
ingredient JJ O
of TO O
the VB O
bulk IN O
drug DT O
or NN O
it VBZ O
has VBN O
multi IN O
ingredients IN O
we JJ O
have NN O
held IN O
that DT O
the JJ O
government NN O
of CC O
india PRP O
s VBZ O
view VBN O
that NNS O
single PRP O
ingredient VBP O
formulators VBN O
alone IN O
should DT O
be NN O
taken IN O
into JJ O
account NN O
for NN O
the IN O
purpose JJ O
of NN O
the NNS O
criteria RB O
in MD O
clause VB O
iii VBN O
of IN O
para NN O
2272 IN O
of DT O
drugs NN O
policy IN O
cannot DT O
be NNS O
said IN O
to NN O
be NN O
against IN O
the NN O
policy CD O
or IN O
otherwise NNS O
unreasonable NN O
84 MD O
sales RB O
of VB O
bulk VBD O
drugs TO O
effected VB O
during IN O
the DT O
year NN O
by CC O
bulk RB O
drug JJ O
producers CD O
including NNS O
some IN O
of NN O
the NNS O
respondents VBD O
herein IN O
would DT O
have NN O
furnished IN O
the JJ O
best NN O
indicia NNS O
of VBG O
domestic DT O
sale IN O
turnover DT O
of NNS O
bulk NN O
drug MD O
but VB O
those VBN O
details DT O
were JJS O
not NN O
disclosed IN O
secondly JJ O
if NN O
the NN O
bulk IN O
drug JJ O
produced NN O
was CC O
consumed DT O
by NNS O
any VBD O
bulk RB O
drug VBN O
producer RB O
or IN O
importer DT O
and JJ O
the NN O
drug VBN O
was VBD O
sold VBN O
in IN O
the DT O
form JJ O
of NN O
formulations NN O
the CC O
satisfies NN O
regarding CC O
the DT O
quantum NN O
of VBD O
bulk VBN O
drug IN O
utilized DT O
in NN O
such IN O
formulations NNS O
and DT O
the NNS O
value VBG O
thereof DT O
must NN O
have IN O
been JJ O
within NN O
the VBN O
knowledge IN O
or JJ O
reach NNS O
of CC O
writ DT O
petitioners NN O
and NN O
there MD O
is VB O
no VBN O
good IN O
reason DT O
why NN O
they CC O
should NN O
withhold IN O
all NN O
this NNS O
relevant CC O
information EX O
and VBZ O
harp DT O
on JJ O
org NN O
data WRB O
there PRP O
is MD O
no VB O
need PDT O
to DT O
resort JJ O
to NN O
guesswork CC O
when NN O
the IN O
actual NN O
figures NNS O
are EX O
available VBZ O
at DT O
the NN O
doorsteps TO O
of VB O
the TO O
respondents VB O
moreover WRB O
some DT O
of JJ O
the NNS O
respondents VBP O
have JJ O
arrived IN O
at DT O
the NNS O
estimates IN O
by DT O
varying NNS O
methods VB O
without DT O
reference IN O
to DT O
actual NNS O
data VBP O
available VBN O
with IN O
them DT O
for NNS O
instance IN O
in VBG O
the NNS O
case IN O
of NN O
the TO O
drug JJ O
cyproflaxacin NNS O
we JJ O
have IN O
adverted PRP O
to IN O
different NN O
methods IN O
of DT O
calculation NN O
given IN O
by DT O
the NN O
writ NN O
petitioners PRP O
which VBP O
yield VBN O
different TO O
results JJ O
if NNS O
we IN O
go NN O
by VBN O
the IN O
estimates DT O
of NN O
turnover NNS O
made WDT O
by VBP O
the JJ O
respondents NNS O
there IN O
is PRP O
vast VBP O
difference IN O
between DT O
the NNS O
value IN O
of NN O
the VBN O
bulk IN O
drug DT O
worked NNS O
out EX O
by VBZ O
them JJ O
and NN O
the IN O
sale DT O
value NN O
of IN O
formulations DT O
moreover JJ O
in NN O
relation VBN O
to RP O
some IN O
of PRP O
the CC O
drugs DT O
there NN O
is NN O
vast IN O
variation NNS O
between RB O
the IN O
quantity NN O
produced TO O
and DT O
imported IN O
and DT O
the NNS O
quantity EX O
said VBZ O
to JJ O
have NN O
been IN O
utilized DT O
in NN O
formulations VBN O
sold CC O
in VBN O
the CC O
market DT O
these NN O
factors VBD O
should TO O
have VB O
put VBN O
the VBN O
high IN O
court NNS O
on VBN O
guard IN O
to DT O
subject NN O
the DT O
petitioners NNS O
version MD O
to VB O
close VBN O
and DT O
critical JJ O
scrutiny NN O
85 IN O
when NN O
the TO O
burden VB O
was DT O
on NNS O
the NN O
writ TO O
petitioners VB O
to CC O
substantiate JJ O
their NN O
plea CD O
of WRB O
violation DT O
of NN O
article VBD O
14 IN O
and DT O
when NN O
the NNS O
plea TO O
predominantly VB O
rested PRP$ O
on NN O
facts IN O
and NN O
figures IN O
the NN O
high CD O
court CC O
should WRB O
have DT O
examined NN O
the RB O
intrinsic VBN O
worth IN O
and NNS O
credibility CC O
of VBZ O
the DT O
version JJ O
put NN O
forward MD O
with VB O
regard VBN O
to DT O
the JJ O
turnover NN O
figures CC O
the NN O
high IN O
court DT O
oversimplified NN O
the VBD O
whole RB O
issue IN O
by NN O
addressing TO O
itself DT O
to NN O
the VBZ O
only DT O
question JJ O
whether NN O
there VBD O
was DT O
effective JJ O
rebuttal NN O
of IN O
the VBG O
averments PRP O
by TO O
the DT O
union JJ O
of NN O
india IN O
the EX O
callousness VBD O
on JJ O
the NN O
part IN O
of DT O
the NNS O
officials IN O
concerned DT O
in NN O
not IN O
meeting VBG O
the DT O
points NN O
raised IN O
squarely DT O
and NN O
leaving IN O
the DT O
scope NNS O
for VBN O
ambiguity IN O
should RB O
not VBG O
in DT O
our NNS O
view VBD O
be RB O
a CC O
ground VBG O
to DT O
accept NN O
whatever IN O
is NN O
falling MD O
rom RB O
the IN O
writ PRP$ O
petitioners NN O
the VB O
material DT O
placed NN O
before TO O
the VB O
court WDT O
should VBZ O
have VBG O
been IN O
critically DT O
examined NN O
before VBZ O
reaching DT O
a NN O
conclusion VBD O
that IN O
article DT O
14 NN O
is MD O
violated VB O
the VBN O
high RB O
court VBN O
should IN O
have VBG O
also DT O
examined NN O
whether WDT O
the NN O
writ CD O
petitioners VBZ O
withheld VBN O
the DT O
relevant JJ O
data NN O
which MD O
they VB O
were RB O
in VBN O
a IN O
position DT O
to NN O
produce NNS O
and VBD O
if DT O
so NN O
what NNS O
would WDT O
be PRP O
its VBD O
effect IN O
none DT O
of NN O
these TO O
aspects VB O
received CC O
attention IN O
of RB O
the WP O
high MD O
court VB O
before PRP$ O
striking NN O
down NN O
the IN O
legislation DT O
the NNS O
high VBD O
court NN O
should IN O
have DT O
realized JJ O
that NN O
those IN O
who VBG O
challenged RP O
the DT O
legislation NN O
should DT O
lay JJ O
firm NN O
factual MD O
foundation VB O
in VBN O
support IN O
of DT O
their WP O
plea VBD O
the DT O
complaint NN O
of MD O
violation VB O
of JJ O
norms JJ O
set NN O
out IN O
in NN O
the IN O
policy PRP$ O
leading NN O
to DT O
the NN O
alleged IN O
infraction NN O
of IN O
article NNS O
14 VBN O
depends RP O
in IN O
the DT O
ultimate NN O
analysis VBG O
on TO O
facts DT O
and VBN O
figures NN O
as IN O
already NN O
observed CD O
org NNS O
data IN O
is DT O
neither JJ O
comprehensive NN O
nor IN O
conclusive NNS O
and CC O
moreover NNS O
in IN O
regard RB O
to VBN O
some JJ O
of NNS O
the VBZ O
drugs DT O
the JJ O
data CC O
does JJ O
not CC O
in RB O
unequivocal IN O
terms NN O
support TO O
the DT O
case IN O
of DT O
the NNS O
writ DT O
petitioners NN O
in VBZ O
such RB O
a IN O
situation JJ O
further NNS O
probe VBP O
and DT O
analysis NN O
was IN O
required DT O
which NN O
the NNS O
high IN O
court JJ O
failed DT O
to NN O
do RB O
the NN O
version CC O
of NN O
writ VBD O
petitioners VBN O
regarding WDT O
the DT O
quantum JJ O
of NN O
turnover VBD O
was TO O
accepted VB O
to DT O
be NN O
correct IN O
on NN O
its NNS O
face VBG O
value DT O
that NN O
apart IN O
in NN O
the VBD O
light VBN O
of TO O
the VB O
clarification JJ O
given IN O
by PRP$ O
us NN O
that NN O
single WDT O
ingredient RB O
formulators IN O
alone DT O
could NN O
be IN O
legitimately DT O
taken NN O
into VBN O
account IN O
in PRP O
the IN O
context JJ O
of NN O
clause NNS O
iii RB O
the MD O
need VB O
for RB O
reconsideration VBN O
by IN O
the NN O
high IN O
court DT O
becomes NN O
inevitable IN O
we NN O
are VBP O
therefore DT O
of NN O
the IN O
view NN O
that IN O
the DT O
crucial JJ O
issues NN O
regarding VBZ O
the JJ O
applicability PRP O
of VBP O
criteria RB O
laid IN O
down DT O
in NN O
para IN O
2272 DT O
of JJ O
the NNS O
drugs VBG O
policy DT O
require NN O
reconsideration IN O
by NNS O
the VBN O
high RB O
court IN O
from JJ O
various CD O
angles IN O
indicated DT O
supra NNS O
in NN O
the VBP O
light NN O
of IN O
the DT O
legal JJ O
position NN O
enunciated IN O
and JJ O
the NNS O
observations VBD O
made NN O
in IN O
this DT O
judgment NN O
86 IN O
we DT O
have JJ O
broadly NN O
indicated VBN O
the CC O
aspects DT O
on NNS O
which VBN O
the IN O
high DT O
court NN O
could CD O
have PRP O
focused VBP O
its RB O
attention VBN O
before DT O
the NNS O
reaching IN O
the WDT O
conclusion DT O
it JJ O
did NN O
nothing MD O
precludes VB O
the VBN O
high PRP$ O
court NN O
from IN O
having DT O
regard VBG O
to DT O
other NN O
aspects PRP O
or VBD O
material NN O
which IN O
it DT O
considers JJ O
relevant NN O
to IN O
test VBG O
the NN O
correctness TO O
of JJ O
the NNS O
writ CC O
petitioners NN O
claims WDT O
however PRP O
we VBZ O
would JJ O
like TO O
to VB O
clarify DT O
one NN O
thing IN O
if DT O
on NN O
reconsideration NNS O
the NNS O
turnover RB O
of PRP O
any MD O
drug VB O
is TO O
found VB O
to CD O
be NN O
very IN O
close IN O
to NN O
the DT O
figure NN O
400 IN O
or DT O
100 NN O
lacs VBZ O
as VBN O
the TO O
case VB O
may RB O
be RB O
the TO O
relevant DT O
criterion NN O
must CD O
be CC O
deemed CD O
to NN O
have IN O
been DT O
satisfied NN O
as MD O
we VB O
said DT O
earlier JJ O
mathematical NN O
accuracy MD O
is VB O
not VBN O
what TO O
is VB O
required VBN O
87 VBN O
there IN O
is PRP O
one VBD O
more RBR O
point JJ O
which NN O
we VBZ O
have RB O
to WP O
deal VBZ O
with VBN O
ie CD O
the EX O
alleged VBZ O
discrimination CD O
between JJR O
one NN O
drug WDT O
and PRP O
another VBP O
the TO O
high VB O
court IN O
upheld NN O
such DT O
plea VBN O
raised NN O
in IN O
rejoinder CD O
affidavit NN O
in CC O
relation DT O
to DT O
the JJ O
drugs NN O
cyproflaxacin VBD O
and JJ O
glipizide NN O
we VBN O
unhesitatingly IN O
vacate NN O
the NN O
findings IN O
of NN O
the TO O
high DT O
court NNS O
in NN O
this CC O
regard NN O
because PRP O
we RB O
are VBP O
of DT O
the NNS O
view IN O
that DT O
the JJ O
reasons NN O
given IN O
by DT O
the NN O
high IN O
court PRP O
for VBP O
upholding IN O
such DT O
plea NN O
are IN O
too DT O
tenuous NNS O
to VBN O
merit IN O
even DT O
prima JJ O
facie NN O
acceptance IN O
88 VBG O
in JJ O
the NN O
case VBP O
of RB O
cyproflaxacin JJ O
in TO O
wpno VB O
3449 RB O
of JJ O
1996 NNS O
it NN O
was CD O
contended IN O
that DT O
two NN O
bulk IN O
drugs NN O
namely IN O
mefenamic JJ O
acid CD O
and IN O
amikacin CD O
sulphate PRP O
were VBD O
wrongly VBN O
and IN O
arbitrarily CD O
deleted NN O
from NNS O
the RB O
dpco JJ O
1995 NN O
it CC O
is JJ O
difficult NN O
to VBD O
comprehend RB O
as CC O
to RB O
how VBN O
there IN O
could DT O
be NN O
infraction CD O
of PRP O
article VBZ O
14 JJ O
merely TO O
because VB O
a IN O
few TO O
bulk WRB O
drugs EX O
were MD O
excluded VB O
from NN O
the IN O
purview NN O
of CD O
dpco RB O
on IN O
a DT O
reconsideration JJ O
the NN O
exclusion NNS O
of VBD O
some VBN O
drugs IN O
even DT O
if NN O
such IN O
exclusion NN O
is IN O
unjustified DT O
cannot NN O
be DT O
a NN O
ground IN O
to DT O
claim NNS O
exclusion RB O
of IN O
other JJ O
drugs NN O
on VBZ O
the VBN O
so MD O
called RB O
principle VB O
of DT O
parity NN O
logically TO O
if VB O
the NN O
high IN O
court JJ O
s NNS O
view IN O
has DT O
to RB O
be JJ O
accepted NN O
the IN O
entire NN O
schedule RB O
should IN O
be DT O
invalidated JJ O
for NN O
the NN O
simple NN O
reason VBZ O
that TO O
one VB O
or VBN O
two DT O
drugs JJ O
which NN O
were MD O
not VB O
eligible VBN O
for IN O
exclusion DT O
in JJ O
the NN O
light WDT O
of CD O
the CC O
policy CD O
guidelines NNS O
were WDT O
excluded VBD O
it RB O
would JJ O
then IN O
lead NN O
to IN O
a DT O
starting NN O
result IN O
frustrating DT O
the NN O
very NNS O
objective VBD O
of VBN O
regulating PRP O
the MD O
price RB O
of VB O
essential TO O
drugs DT O
that VBG O
apart NN O
the VBG O
turnover DT O
figures RB O
of JJ O
the IN O
said VBG O
two DT O
drugs NN O
furnished IN O
by JJ O
the NNS O
writ WDT O
petitioner VBP O
and DT O
referred NN O
to NNS O
by IN O
the DT O
high VBD O
court CD O
do NNS O
not VBN O
established IN O
that DT O
they NN O
fall NN O
within CC O
the VBN O
policy TO O
guidelines IN O
regarding DT O
mefenamic JJ O
acid NN O
what VBP O
all RB O
is VBN O
stated IN O
in PRP O
paragraph VBP O
16 IN O
of DT O
the NN O
rejoinder NNS O
affidavit VBG O
is JJ O
that NN O
the WP O
turnover DT O
of VBZ O
this VBN O
drug IN O
has NN O
been CD O
over IN O
rs DT O
4 NN O
crores NN O
between VBZ O
1988 IN O
89 DT O
to NN O
1991 IN O
92 DT O
and NN O
yet VBZ O
it VBN O
was IN O
excluded JJ O
for CD O
reasons NNS O
not IN O
known CD O
to CD O
the TO O
petitioners CD O
nothing CD O
has CC O
been RB O
stated PRP O
as VBD O
to VBN O
how IN O
the NNS O
turnover RB O
for VBN O
the TO O
relevant DT O
year NNS O
was NN O
arrived VBZ O
at VBN O
no VBN O
information IN O
was TO O
furnished WRB O
regarding DT O
the NN O
number IN O
of DT O
bulk JJ O
drug NN O
producers VBD O
and VBN O
formulators IN O
and DT O
their NN O
market VBD O
share VBN O
evidently VBG O
the DT O
petitioner NN O
made IN O
only JJ O
a NN O
halfhearted NNS O
attempt CC O
to NNS O
put CC O
forward PRP$ O
a NN O
plea NN O
of RB O
discrimination DT O
but NN O
it VBD O
succeeded RB O
in DT O
its JJ O
attempt NN O
coming TO O
to VB O
the RP O
other DT O
drug NN O
amikacin IN O
sulphate NN O
even CC O
according PRP O
to VBD O
the IN O
petitioner PRP$ O
the NN O
import VBG O
value TO O
of DT O
the JJ O
drug NN O
in NNS O
1989 VB O
90 RB O
was VBG O
rs TO O
35 DT O
crores NN O
which DT O
is NN O
much NN O
below IN O
the DT O
limit NN O
of IN O
rs CD O
4 CD O
crores VBD O
and JJ O
even CD O
if NNS O
there WDT O
was VBZ O
a RB O
single IN O
formulator DT O
having NN O
a IN O
market NN O
share CD O
in NNS O
excess CC O
of RB O
40 IN O
that EX O
does VBD O
not DT O
make JJ O
any NN O
difference VBG O
that DT O
apart NN O
the NN O
government IN O
of NN O
india IN O
clarified CD O
in WDT O
one VBZ O
of RB O
the VB O
counter DT O
affidavits NN O
filed WDT O
in VBZ O
the DT O
high NN O
court IN O
that NN O
on VBN O
the IN O
scrutiny CD O
and IN O
verification DT O
of NN O
details NNS O
submitted VBN O
by IN O
the DT O
manufacturers JJ O
these NN O
two WDT O
drugs IN O
were DT O
subsequently NN O
deleted CC O
from NN O
the IN O
first NNS O
schedule VBN O
having IN O
regard DT O
to NNS O
the DT O
criteria CD O
laid NNS O
down VBD O
in RB O
the VBN O
policy IN O
we DT O
have JJ O
therefore NN O
no VBG O
hesitation NN O
in TO O
reversing DT O
the NN O
conclusion VBD O
of RB O
the IN O
high DT O
court NN O
that PRP O
the VBP O
exclusion RB O
of DT O
the NN O
said IN O
two VBG O
drugs DT O
from NN O
dpco IN O
amounted DT O
to JJ O
hostile NN O
discrimination IN O
89 DT O
regarding NN O
glipizide IN O
the DT O
plea VBD O
of CD O
discrimination NNS O
between IN O
this NN O
drug VBN O
and TO O
another VB O
anti NN O
diabetic CD O
drug VBG O
known NN O
as DT O
insulin NN O
found IN O
favour NN O
with IN O
the DT O
high NN O
court CC O
the DT O
high JJ O
court JJ O
in NN O
paragraph VBN O
90 IN O
of NN O
the VBD O
judgment RB O
referred IN O
to DT O
the JJ O
argument NN O
that DT O
insulin JJ O
having NN O
441 IN O
lacs NN O
turnover CD O
as IN O
on DT O
31st NN O
march VBD O
1990 TO O
was DT O
included NN O
in IN O
dpco NN O
of VBG O
1995 CD O
but JJ O
subsequently NN O
excluded IN O
from IN O
price CD O
control NN O
and CD O
held VBD O
that VBN O
there IN O
was NN O
discrimination IN O
on CD O
that CC O
account RB O
the VBD O
high IN O
court NN O
evidently NN O
proceeded CC O
on VBD O
an IN O
erroneous EX O
assumption VBD O
that NN O
insulin IN O
was DT O
excluded VBP O
from DT O
the JJ O
schedule NN O
the RB O
averments VBD O
in IN O
paragraph DT O
22 JJ O
of NN O
the IN O
writ NN O
petition VBD O
no VBN O
5219 IN O
1996 DT O
are NN O
otherwise DT O
the NNS O
plea IN O
of NN O
discrimination CD O
was IN O
aimed DT O
at NN O
the NN O
drug DT O
known CD O
as CD O
glibelclamide VBP O
which RB O
was DT O
excluded NN O
from IN O
the NN O
dpco VBD O
of VBN O
1987 IN O
and DT O
continued NN O
to VBN O
remain IN O
excluded NN O
from WDT O
the VBD O
dpco VBN O
of IN O
1995 DT O
the NN O
respondent IN O
did CD O
not CC O
even VBD O
aver TO O
that VB O
the JJ O
said IN O
drug DT O
had NN O
the IN O
turnover CD O
of DT O
more NN O
than VBD O
100 RB O
lacs RB O
and VB O
therefore IN O
it DT O
would VBD O
fall NN O
within VBD O
the DT O
mischief NN O
of IN O
clause JJR O
ii IN O
on CD O
the NN O
basis CC O
of NN O
a PRP O
bald MD O
plea VB O
the IN O
infraction DT O
of NN O
article IN O
14 NN O
ought NN O
not IN O
to DT O
have NN O
been IN O
countenanced DT O
the NN O
finding NN O
of DT O
the NN O
high IN O
court NN O
in CD O
this MD O
regard RB O
is TO O
palpably VB O
wrong VBN O
9 VBN O
we DT O
now NN O
summarize IN O
the DT O
conclusions JJ O
as NN O
under IN O
1 DT O
where NN O
the VBZ O
central RB O
government JJ O
as CD O
the PRP O
delegate RB O
of VBP O
legislative DT O
power NNS O
announces IN O
a IN O
rational CD O
policy WRB O
in DT O
keeping JJ O
with NN O
the IN O
purposes DT O
of NN O
enabling IN O
legislation JJ O
and NN O
even VBZ O
lays DT O
down JJ O
specific NN O
criteria IN O
to VBG O
promote IN O
the DT O
policy NNS O
the IN O
criteria VBG O
so NN O
evolved CC O
become RB O
the NNS O
guide RP O
posts JJ O
of NNS O
its TO O
legislative VB O
action DT O
while NN O
classifying DT O
the NNS O
drugs RB O
for VBD O
the VB O
purpose DT O
of JJ O
price NNS O
control IN O
it PRP$ O
is JJ O
not NN O
open IN O
to VBG O
the DT O
government NNS O
to IN O
flout DT O
or NN O
debilitate IN O
the NN O
set NN O
norms PRP O
which VBZ O
it RB O
professed JJ O
to TO O
follow DT O
in NN O
the TO O
interest VB O
of CC O
transparency VB O
and DT O
objectivity NN O
otherwise NNS O
there WDT O
will PRP O
be VBD O
an TO O
element VB O
of IN O
arbitrariness DT O
and NN O
the IN O
delegated NN O
legislation CC O
will NN O
not RB O
withstand EX O
the MD O
test VB O
of DT O
article NN O
14 IN O
2 NN O
the CC O
expression DT O
turnover JJ O
in NN O
drug MD O
policy RB O
1994 VB O
represents DT O
the NN O
sale IN O
value NN O
of CD O
bulk CD O
drug DT O
sold NN O
as NN O
such IN O
or NN O
in NN O
the CD O
form VBZ O
of DT O
formulations NN O
3 NN O
export IN O
sales JJ O
should NN O
not VBN O
be IN O
taken JJ O
into CC O
account IN O
while DT O
computing NN O
turnover IN O
4 NNS O
the CD O
sum NN O
total NNS O
of MD O
production RB O
and VB O
imports VBN O
of IN O
bulk NN O
drug IN O
cannot VBG O
be RB O
equated CD O
to DT O
turnover NN O
though NN O
they IN O
are NN O
not CC O
altogether NNS O
irrelevant IN O
in JJ O
calculating NN O
the MD O
turnover RB O
5 VB O
org VBN O
data TO O
does VB O
not IN O
give PRP O
exhaustive VBP O
account RB O
of RB O
turn JJ O
over IN O
of VBG O
bulk DT O
drug NN O
it CD O
may JJ O
furnish NN O
the VBZ O
basis RB O
for VB O
estimating JJ O
the NN O
turnover IN O
but NN O
is IN O
not IN O
the JJ O
sole NN O
guide PRP O
6 MD O
for VB O
the DT O
purpose NN O
of IN O
criterion VBG O
no DT O
iii NN O
of CC O
the VBZ O
drug RB O
policy DT O
the JJ O
single NN O
ingredient CD O
formulators IN O
alone DT O
ought NN O
to IN O
be NN O
taken DT O
into NN O
account IN O
as DT O
clarified NN O
by NN O
the DT O
govt JJ O
of NN O
india NNS O
7 RB O
burden MD O
lies TO O
on VB O
those VBN O
who IN O
challenge NN O
the IN O
legislation VBN O
on IN O
the DT O
ground NN O
of IN O
violation JJ O
of CD O
article NN O
14 NNS O
to IN O
make DT O
out WP O
their VBP O
case DT O
by NN O
furnishing IN O
all DT O
the NN O
relevant IN O
material NN O
which IN O
is NN O
within CD O
their TO O
reach VB O
and RP O
knowledge PRP$ O
there NN O
should IN O
be VBG O
frank PDT O
disclosure DT O
of JJ O
material NN O
facts WDT O
more VBZ O
so IN O
when PRP$ O
the NN O
plea CC O
is NN O
founded RB O
on MD O
certain VB O
factual JJ O
aspects NN O
the IN O
mere JJ O
vagueness NNS O
or RBR O
lack RB O
of WRB O
clarity DT O
in NN O
the VBZ O
stand VBN O
taken IN O
by JJ O
the JJ O
union VBZ O
of DT O
india JJ O
does NN O
not CC O
by NN O
itself IN O
advance NN O
the IN O
case DT O
of NN O
the VBN O
writ IN O
petitioners DT O
8 NN O
the IN O
plea NN O
of VBZ O
writ RB O
petitioners IN O
ought PRP O
to VB O
have DT O
been NN O
tested IN O
and DT O
subjected NN O
to NNS O
scrutiny CD O
in DT O
the NN O
light IN O
of NN O
all NNS O
relevant MD O
factors TO O
instead VB O
of VBN O
merely VBN O
considering CC O
whether VBN O
the TO O
particulars VB O
furnished IN O
by DT O
the NN O
petitioners IN O
were DT O
effectively JJ O
controverted NNS O
or RB O
not IN O
such RB O
an VBG O
approach IN O
of DT O
the NNS O
high VBN O
court IN O
is DT O
wholly NNS O
impermissible VBD O
while RB O
deciding VBN O
the CC O
validity RB O
of JJ O
legislation DT O
plenary NN O
or IN O
delegated DT O
from JJ O
the NN O
stand VBZ O
point RB O
of JJ O
article IN O
14 VBG O
9 DT O
the NN O
plea IN O
of NN O
discrimination NN O
between CC O
one VBN O
drug IN O
and DT O
another NN O
is NN O
unfounded IN O
and NN O
should CD O
not CD O
have DT O
been NN O
accepted IN O
by NN O
the IN O
high CD O
court NN O
10 CC O
in DT O
the VBZ O
result JJ O
the CC O
judgment MD O
of RB O
the VB O
high VBN O
court VBN O
is IN O
set DT O
aside JJ O
and NN O
the CD O
writ IN O
petitions DT O
out NN O
of DT O
which NN O
these IN O
appeals DT O
arise JJ O
shall NN O
stand VBZ O
restored VBN O
to RB O
the CC O
file DT O
of NN O
the NNS O
high IN O
court IN O
and WDT O
the DT O
high NNS O
court VBP O
will MD O
have VB O
to VBN O
consider TO O
afresh DT O
the NN O
relevant IN O
aspects DT O
concerning JJ O
the NN O
criteria CC O
laid DT O
down JJ O
in NN O
para MD O
2272 VB O
of TO O
the VB O
drug PDT O
policy DT O
1994 JJ O
in NNS O
relation VBG O
to DT O
each NN O
drug VBD O
having RB O
due IN O
regard JJ O
to CD O
the IN O
observations DT O
made NN O
in NN O
the CD O
judgment IN O
the NN O
high TO O
court DT O
may NN O
endeavour VBG O
to JJ O
expedite NN O
hearing TO O
of DT O
the NNS O
writ VBN O
petitions IN O
11 DT O
the NN O
appeals DT O
are JJ O
accordingly NN O
allowed MD O
without VB O
costs TO O
we VB O
also NN O
consider IN O
it DT O
just NN O
and NNS O
proper CD O
to DT O
give NNS O
liberty VBP O
to RB O
the VBN O
appellant IN O
and NNS O
the PRP O
concerned RB O
statutory VBP O
authorities PRP O
to RB O
recover CC O
50 JJ O
of TO O
the VB O
over NN O
charged TO O
amounts DT O
pending NN O
fresh CC O
determination DT O
by JJ O
the JJ O
high NNS O
court TO O
accordingly VB O
we CD O
direct IN O
stay DT O
of NN O
recovery VBD O
of NNS O
50 VBG O
of JJ O
the NN O
overcharged IN O
amount DT O
subject JJ O
to NN O
the RB O
payment PRP O
of VBP O
remaining NN O
50 IN O
within NN O
the IN O
period CD O
of IN O
four DT O
weeks JJ O
from NN O
the NN O
date TO O
of DT O
communication NN O
of IN O
the VBG O
amount CD O
payable IN O
by DT O
each NN O
of IN O
the CD O
writ NNS O
petitioners IN O
